Cantel Medical (CMD) 10-K 28 Sep 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2017	Aug. 31, 2017	Jan. 31, 2017
Document and Entity Information
Entity Registrant Name	CANTEL MEDICAL CORP
Entity Central Index Key	19,446
Document Type	10-K
Document Period End Date	Jul. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 2,767,926,147
Entity Common Stock, Shares Outstanding		41,727,461
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Current assets:
Cash and cash equivalents	$ 36,584	$ 28,367
Accounts receivable, net of allowance for doubtful accounts of $1,808 in 2017 and $1,850 in 2016	110,656	93,332
Inventories, net	98,724	91,486
Prepaid expenses and other current assets	11,407	9,557
Total current assets	257,371	222,742
Property and equipment, net	88,338	74,604
Intangible assets, net	124,512	111,719
Goodwill	311,445	280,318
Other assets	4,707	5,149
Total assets	786,373	694,532
Current liabilities:
Accounts payable	27,469	26,263
Compensation payable	27,468	25,555
Accrued expenses	23,393	20,283
Deferred revenue	25,282	20,173
Income taxes payable	3,167	4,061
Total current liabilities	106,779	96,335
Long-term debt	126,000	116,000
Deferred income taxes	24,714	23,579
Other long-term liabilities	4,948	4,248
Total liabilities	262,441	240,162
Commitments and Contingencies (Note 12)
Stockholders’ equity:
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued	0	0
Common Stock, par value $.10 per share; authorized 75,000,000 shares; issued 2017 - 46,194,370 shares, outstanding 2017 - 41,728,934 shares; issued 2016 - 46,084,047 shares, outstanding 2016 - 41,708,214 shares	4,619	4,608
Additional paid-in capital	174,602	165,573
Retained earnings	407,590	342,053
Accumulated other comprehensive loss	(9,900)	(11,795)
Treasury Stock, at cost; 2017 - 4,465,440 shares; 2016 - 4,375,833 shares	(52,979)	(46,069)
Total stockholders’ equity	523,932	454,370
Total liabilities and stockholders' equity	$ 786,373	$ 694,532

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 1,808	$ 1,850
Preferred Stock, par value (in dollars per share)	$ 1	$ 1
Preferred Stock, authorized shares	1,000,000	1,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common Stock, authorized shares	75,000,000	75,000,000
Common Stock, shares issued	46,194,370	46,084,047
Common Stock, shares outstanding	41,728,934	41,708,214
Treasury Stock, shares	4,465,440	4,375,833

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Net sales
Product sales	$ 684,678	$ 584,750	$ 493,656
Product service	85,479	80,005	71,348
Total net sales	770,157	664,755	565,004
Cost of sales
Product sales	343,641	300,704	260,903
Product service	59,356	54,865	50,634
Total cost of sales	402,997	355,569	311,537
Gross profit	367,160	309,186	253,467
Expenses:
Selling	116,113	99,062	80,787
General and administrative	122,270	97,463	77,897
Research and development	18,367	15,410	14,022
Total operating expenses	256,750	211,935	172,706
Income from operations	110,410	97,251	80,761
Interest expense, net	4,303	3,320	2,364
Other income	(126)	0	0
Loss on sale of business	0	0	2,206
Income before income taxes	106,233	93,931	76,191
Income taxes	34,855	33,978	28,238
Net income	$ 71,378	$ 59,953	$ 47,953
Earnings per common share:
Basic (in dollars per share)	$ 1.71	$ 1.44	$ 1.16
Diluted (in dollars per share)	1.71	1.44	1.15
Dividends per common share (in dollars per share)	$ 0.14	$ 0.12	$ 0.10

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 71,378	$ 59,953	$ 47,953
Other comprehensive income (loss):
Foreign currency translation	1,895	(13,019)	(7,064)
Reclassification adjustment to loss on sale of business for foreign currency translation gain included in net income during the year	0	0	(1,264)
Total other comprehensive income (loss)	1,895	(13,019)	(8,328)
Comprehensive income	$ 73,273	$ 46,934	$ 39,625

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock, at cost
Balance (in shares) at Jul. 31, 2014		41,442,260
Balance at Jul. 31, 2014	$ 365,246	$ 4,564	$ 146,048	$ 243,306	$ 9,552	$ (38,224)
Increase (Decrease) in Stockholders' Equity
Exercises of options (in shares)		130,911
Exercises of options	608	$ 13	981			(386)
Repurchases of shares (in shares)		(100,286)
Repurchases of shares	(3,727)					(3,727)
Stock-based compensation	5,867		5,867
Issuance of restricted stock (in shares)		144,278
Issuance of restricted stock		$ 15	(15)
Cancellations of restricted stock (in shares)		(12,804)
Cancellations of restricted stock		$ (1)	1
Excess tax benefit from exercises of stock options and vesting of restricted stock	3,168		3,168
Dividends on common stock	(4,154)			(4,154)
Net income	47,953			47,953
Other comprehensive income (loss)	(8,328)				(8,328)
Balance (in shares) at Jul. 31, 2015		41,604,359
Balance at Jul. 31, 2015	406,633	$ 4,591	156,050	287,105	1,224	(42,337)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(67,038)
Repurchases of shares	(3,732)					(3,732)
Stock-based compensation	8,361		8,361
Issuance of restricted stock (in shares)		175,700
Issuance of restricted stock		$ 17	(17)
Cancellations of restricted stock (in shares)		(4,807)
Excess tax benefit from exercises of stock options and vesting of restricted stock	1,179		1,179
Dividends on common stock	(5,005)			(5,005)
Net income	59,953			59,953
Other comprehensive income (loss)	$ (13,019)				(13,019)
Balance (in shares) at Jul. 31, 2016	41,708,214	41,708,214
Balance at Jul. 31, 2016	$ 454,370	$ 4,608	165,573	342,053	(11,795)	(46,069)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(89,607)
Repurchases of shares	(6,910)					(6,910)
Stock-based compensation	8,844		8,844
Issuance of restricted stock (in shares)		116,506
Issuance of restricted stock		$ 12	(12)
Cancellations of restricted stock (in shares)		(6,179)
Cancellations of restricted stock		$ (1)	1
Excess tax benefit from exercises of stock options and vesting of restricted stock	196		196
Dividends on common stock	(5,841)			(5,841)
Net income	71,378			71,378
Other comprehensive income (loss)	$ 1,895				1,895
Balance (in shares) at Jul. 31, 2017	41,728,934	41,728,934
Balance at Jul. 31, 2017	$ 523,932	$ 4,619	$ 174,602	$ 407,590	$ (9,900)	$ (52,979)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Cash flows from operating activities
Net income	$ 71,378	$ 59,953	$ 47,953
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	15,045	11,989	10,692
Amortization	18,407	13,095	13,265
Stock-based compensation expense	8,844	8,361	5,867
Amortization of debt issuance costs	401	401	401
Loss on disposal of fixed assets	966	553	360
Loss on sale of business	0	0	2,206
Impairment of assets	0	0	1,287
Fair value adjustments to acquisition related liabilities	(265)	(687)	(2,585)
Deferred income taxes	118	(1,710)	(1,449)
Excess tax benefits from stock-based compensation	0	(1,179)	(3,168)
Changes in assets and liabilities, net of effects of business acquisitions/divestiture:
Accounts receivable	(12,860)	(12,729)	(3,905)
Inventories	887	(15,558)	(10,075)
Prepaid expenses and other current assets	(1,005)	(2,850)	(2,996)
Accounts payable and other current liabilities	7,039	17,657	(3,347)
Income taxes	(895)	2,972	4,564
Other assets and liabilities	133	0	0
Net cash provided by operating activities	108,193	80,268	59,070
Cash flows from investing activities
Capital expenditures	(27,065)	(18,889)	(12,760)
Proceeds from disposal of fixed assets	47	96	25
Proceeds from sale of business, net of cash retained and disposal costs	0	0	3,767
Acquisition of businesses, net of cash acquired	(70,044)	(94,528)	(43,567)
Other, net	0	339	241
Net cash used in investing activities	(97,062)	(112,982)	(52,294)
Cash flows from financing activities
Borrowings under revolving credit facility	74,000	96,500	47,000
Repayments under revolving credit facility	(64,000)	(59,000)	(49,000)
Proceeds from exercises of stock options	0	0	608
Dividends paid	(5,841)	(5,005)	(4,154)
Excess tax benefits from stock-based compensation	0	1,179	3,168
Purchases of treasury stock	(6,910)	(3,732)	(3,727)
Net cash (used in) provided by financing activities	(2,751)	29,942	(6,105)
Effect of exchange rate changes on cash and cash equivalents	(163)	(581)	(732)
Increase (decrease) in cash and cash equivalents	8,217	(3,353)	(61)
Cash and cash equivalents at beginning of period	28,367	31,720	31,781
Cash and cash equivalents at end of period	36,584	28,367	31,720
Supplemental disclosures of cash flow information:
Cash interest payments	3,455	3,001	1,970
Cash income tax payments	$ 35,858	$ 33,559	$ 25,239

Business Description

Business Description	12 Months Ended
	Jul. 31, 2017
Business Description
Business Description	Business Description Throughout this document, references to “Cantel,” “us,” “we,” “our,” and the “Company” are references to Cantel Medical Corp. and its subsidiaries, except where the context makes it clear the reference is to Cantel itself and not its subsidiaries. Unless otherwise indicated, references in this Form 10-K to 2017 , 2016 , 2015 or “fiscal” 2017 , 2016 , 2015 or other years refer to our fiscal year ended July 31 of that respective year, and references to 2017 or “fiscal” 2018 refer to our fiscal year ending July 31, 2018 . Cantel is a leading provider of infection prevention products and services in the healthcare market, specializing in the following reportable segments: Endoscopy: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products. Water Purification and Filtration: designs, develops, manufactures, sells and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Healthcare Disposables: designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. In addition, through April 7, 2015, we had another operating segment, known as Specialty Packaging. This segment included specialty packaging and thermal control products, as well as related compliance training, for the transport of infectious and biological specimens and thermally sensitive pharmaceutical, medical and other products. The Specialty Packaging operating segment, which comprised the Other reporting segment for financial reporting purposes, was divested on April 7, 2015. See Note 17, "Information as to Operating Segments and Foreign and Domestic Operations." Most of our equipment, consumables and supplies are used to help prevent the occurrence or spread of infections.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The following is a summary of our significant accounting policies used to prepare our consolidated financial statements. Principles of Consolidation The consolidated financial statements include the accounts of Cantel and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the current year's presentation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, we evaluate the adequacy of our reserves and the estimates used in calculations of reserves as well as other judgmental financial statement items, including, but not limited to: collectability of accounts receivable, volume rebates and trade-in allowances, inventory values and obsolescence reserves, warranty reserves, contingent consideration, contingent guaranteed obligations, depreciation and amortization periods, deferred income taxes, goodwill and intangible assets, impairment of long-lived assets, unrecognized tax benefits for uncertain tax positions, reserves for legal exposure, stock-based compensation and expense accruals. Such estimates and assumptions are subjective in nature. We reflect such amounts based upon the most recent information available. Subsequent Events We have evaluated subsequent events for disclosure through the date of issuance of the accompanying consolidated financial statements. Revenue Recognition Revenue on product sales is recognized as products are shipped to customers and title passes. The passing of title is determined based upon the FOB terms specified for each shipment. With respect to endoscopy and dialysis products, shipment terms are generally FOB origin for common carrier and when our distribution fleet is utilized (except for one large customer in dialysis and several endoscopy customers whereby all products are shipped FOB destination). With respect to water purification and filtration and healthcare disposable products, shipment terms may be either FOB origin or destination. Customer acceptance for the majority of our product sales occurs at the time of delivery. With respect to a portion of water purification and filtration and endoscopy product sales, equipment is sold as part of a system for which the equipment is functionally interdependent or the customer’s purchase order specifies “ship-complete” as a condition of delivery; revenue recognition on such sales is deferred until all equipment has been delivered, or post-delivery obligations such as installation have been substantially fulfilled such that the products are deemed functional by the end-user. All shipping and handling fees invoiced to customers, such as freight, are recorded as revenue (and related costs are included within cost of sales) at the time the sale is recognized. A portion of our endoscopy, water purification and filtration and dialysis sales are recognized as multiple element arrangements, whereby revenue is allocated to the equipment, installation and consumable components based upon vendor specific objective evidence, which includes comparable historical transactions of similar equipment, installation and consumables sold as stand-alone components. If vendor-specific objective evidence of selling price is not available, we allocate revenue to the elements of the bundled arrangement using the estimated selling price method in order to qualify the components as separate units of accounting. Revenue on the equipment and consumables components are recognized as the equipment or consumable is shipped to customers and title passes. Revenue on the installation component is recognized when the installation is complete. A portion of our healthcare disposables sales relating to the mail-in spore test kit is recorded as deferred revenue when initially sold. We recognize the revenue on these test kits using an estimate based on historical experience of the amount of time that elapses from the point of sale to when the kit is returned to us and we communicate to the customer the results of the required laboratory test. The related cost of the kits is recorded in inventory and recognized in cost of sales as the revenue is earned. Revenue on service sales is recognized when repairs are completed at the customer’s location or when repairs are completed at our facilities and the products are shipped to customers. With respect to certain service contracts in our Endoscopy and Water Purification and Filtration operating segments, service revenue is recognized on a straight-line basis over the contractual term of the arrangement. Our endoscopy products and services are sold directly to hospitals and other end-users in the United States and primarily to distributors internationally except for the United Kingdom, Italy, Netherlands, Singapore, China and Germany where we sell directly to hospitals and other end-users. Water purification and filtration products and services are sold directly to hospitals, dialysis clinics, pharmaceutical and biotechnology companies, laboratories, medical products and service companies and other end-users as well as through third-party distributors. The majority of our healthcare disposable products are sold to third party distributors, and with respect to some of our sterility assurance products, to hospitals, surgery centers, physician and dental offices, dental schools, medical research companies, laboratories and other end-users. The majority of our dialysis products are sold to dialysis clinics and hospitals. Sales to all of these customers follow our revenue recognition policies. None of our sales contain right-of-return provisions. Customer claims for credit or return due to damage, defect, shortage or other reason must be pre-approved by us before credit is issued or such product is accepted for return. No cash discounts for early payment are offered except with respect to a small portion of our product sales in each segment. We do not offer price protection, although advance pricing contracts or required notice periods prior to implementation of price increases exist for certain customers with respect to many of our products. With respect to certain of our dialysis, healthcare disposables, water purification and filtration and endoscopy customers, rebates are provided; such rebates, which consist primarily of volume rebates, are provided for as a reduction of sales at the time of revenue recognition and amounted to $6,291 , $5,944 , and $5,597 in fiscal 2017 , 2016 , and 2015 , respectively. Such allowances are determined based on estimated projections of sales volume for the entire rebate periods. If it becomes known that sales volume to customers will deviate from original projections, the rebate provisions originally established would be adjusted accordingly. Translation of Foreign Currency Financial Statements Assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at year-end exchange rates; sales and expenses are translated using average exchange rates during the year. The cumulative effect of the translation of the accounts of the foreign subsidiaries is presented as a component of accumulated other comprehensive income or loss. Foreign exchange gains and losses related to the purchase of inventories denominated in foreign currencies are included in cost of sales and foreign exchange gains and losses related to the incurrence of operating costs denominated in foreign currencies and the conversion of foreign assets and liabilities into functional currencies are included in general and administrative expenses. Cash and Cash Equivalents We consider all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist of amounts due to us from normal business activities. Allowances for doubtful accounts are reserves for the estimated loss from the inability of customers to make required payments. We use historical experience as well as current market information in determining the estimate. While actual losses have historically been within management’s expectations and provisions established, if the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Alternatively, if certain customers paid their delinquent receivables, reductions in allowances may be required. Inventories Inventories consist of raw materials, work-in-process and finished products which are sold in the ordinary course of our business and are stated at the lower of cost (first-in, first-out) or market. In assessing the value of inventories, we must make estimates and judgments regarding reserves required for product obsolescence, aging of inventories and other issues potentially affecting the saleable condition of products. In performing such evaluations, we use historical experience as well as current market information. With few exceptions, the saleable value of our inventories has historically been within management’s expectation and provisions established, however, rapid changes in the market due to competition, technology and various other factors could impact the value of our inventories, resulting in the need for additional reserves. Property and Equipment Property and equipment are stated at cost. Additions and improvements are capitalized, while maintenance and repair costs are expensed. When assets are retired or otherwise disposed, the cost and related accumulated depreciation or amortization is removed from the respective accounts and any resulting gain or loss is included in income. Depreciation and amortization is provided on the straight-line method over the estimated useful lives of the assets which generally range from 2 - 15 years for furniture and equipment, 5 - 32 years for buildings and improvements and the shorter of the life of the asset or the life of the lease for leasehold improvements. Depreciation expense related to property and equipment in fiscal 2017 , 2016 and 2015 was $15,045 , $11,989 and $10,692 , respectively. Goodwill and Intangible Assets Certain of our identifiable intangible assets, including customer relationships, technology, brand names, non-compete agreements and patents, are amortized using the straight-line method over their estimated useful lives which range from 3 to 20 years. Additionally, we have recorded goodwill and trademarks and trade names, all of which have indefinite useful lives and are therefore not amortized. All of our intangible assets and goodwill are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and goodwill and intangible assets with indefinite lives are reviewed for impairment at least annually . Our management is responsible for determining if impairment exists and considers a number of factors, including third-party valuations, when making these determinations. We first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount before proceeding to step one of the two-step quantitative goodwill impairment test, if necessary. Such qualitative factors that are assessed include evaluating a segment’s financial performance, industry and market conditions, macroeconomic conditions and specific issues that can directly affect the segment such as changes in business strategies, competition, supplier relationships, operating costs, regulatory matters, litigation and the composition of the segment’s assets due to acquisitions or other events. At July 31, 2017 , because we determined through qualitative factors that the fair values of our Endoscopy, Water Purification and Filtration and Healthcare Disposables segments were unlikely to be less than the carrying value, we did not proceed to step one of the two-step quantitative goodwill impairment test for those three segments. We performed step one of the two-step quantitative goodwill impairment test for Dialysis due to the continuing shift by our customers from reusable to single-use dialyzers, which is having an adverse impact on our business and is expected to continue. In performing a detailed quantitative review for goodwill impairment, management uses a two-step process that begins with an estimation of the fair value of the related reporting units by using weighted fair value results of the discounted cash flow methodology, as well as the market multiple and comparable transaction methodologies, where applicable. The first step is a review for potential impairment, and the second step measures the amount of impairment, if any. We perform our annual impairment review for indefinite lived intangibles by first assessing qualitative factors, such as those described above, to determine whether it is more likely than not that the fair value of such assets is less than the carrying values, and if necessary, we perform a quantitative analysis comparing the current fair value of our indefinite lived intangibles assets to their carrying values. At July 31, 2017 , because we determined through qualitative factors that the fair values of all of our indefinite lived intangible assets were unlikely to be less than the carrying value, we did not perform a quantitative analysis for those assets. With respect to amortizable intangible assets when impairment indicators are present, management would determine whether expected future non-discounted cash flows would be sufficient to recover the carrying value of the assets; if not, the carrying value of the assets would be adjusted to their fair value. Management concluded that none of our intangible assets or goodwill was impaired as of July 31, 2017 . Long-Lived Assets We evaluate the carrying value of long-lived assets including property, equipment and other assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. An assessment is made to determine if the sum of the expected future non-discounted cash flows from the use of the assets and eventual disposition is less than the carrying value. If the sum of the expected non-discounted cash flows is less than the carrying value, an impairment loss is recognized based on fair value. With the exception of the impairment on an acquired license, our historical assessments of our long-lived assets have not differed significantly from the actual amounts realized. See Note 8, "Intangibles and Goodwill." However, the determination of fair value requires us to make certain assumptions and estimates and is highly subjective. On July 31, 2017 , management concluded that no other events or changes in circumstances have occurred that would indicate that the carrying amount of our long-lived assets may not be recoverable. Other Assets Debt issuance costs associated with our credit facilities are amortized to interest expense over the life of the credit facilities. As of July 31, 2017 and 2016 , such debt issuance costs, net of related amortization, were included in other assets and amounted to $580 and $946 , respectively. Warranties We provide for estimated costs that may be incurred to remedy deficiencies of quality or performance of our products at the time of revenue recognition. Most of our products have a one year warranty, although certain endoscopy and water purification and filtration products that require installation may carry a warranty period of up to 24 months . Additionally, many of our consumables, accessories, parts and service have a 90 day warranty. We record provisions for product warranties as a component of cost of sales based upon an estimate of the amounts necessary to settle existing and future claims on products sold. The historical relationship of warranty costs to products sold is the primary basis for the estimate. A significant increase in third party service repair rates, the cost and availability of parts or the frequency of claims could have a material impact on our results for the period or periods in which such claims or additional costs materialize. Management reviews its warranty exposure periodically and believes that the warranty reserves are adequate; however, actual claims incurred could differ from original estimates, requiring adjustments to the reserves. Stock-Based Compensation Stock compensation expense is recognized for any option or stock award grant based upon the fair value of the award. Our stock options and time-based stock awards are subject to graded vesting in which portions of the award vest ratably over the vesting period. We recognize compensation expense for awards subject to graded vesting using the straight-line basis over the vesting period. In October 2016, we granted for the first time to certain employees equity awards with performance conditions and equity awards with market conditions. We recognize compensation expense for the awards with performance conditions using the accelerated attribution method over the requisite service period for each separately vesting portion of the award when it is probable that the performance condition will be achieved. We record expense for the awards with market conditions ratably over the vesting period regardless of whether the market condition is satisfied. As a result of the adoption of ASU 2016-09 on August 1, 2016, we have elected to account for forfeitures as they occur, rather than estimate forfeitures over the course of the vesting period. We determine the fair value if each time-based stock award and performance-based stock award by using the closing market price of our common stock on the last trading date immediately prior to the date of grant. We determine the fair value of each award with market conditions using a Monte Carlo simulation model on the date of grant. We estimate the fair value of each option grant on the date of grant using the Black Scholes option valuation model. The determination of fair value using valuation models is affected by our stock price as well as assumptions regarding a number of subjective variables. These variables may include, but are not limited to, the expected price volatility over the term of the expected equity award life, the expected dividend yield, the expected equity award life, the probability of meeting performance objectives and the stock price of our peers in the S&P Healthcare Equipment Index. Advertising Costs Our policy is to expense advertising costs as they are incurred. Advertising costs charged to expense were $3,694 , $3,349 and $3,333 in fiscal 2017 , 2016 and 2015 , respectively. Income Taxes Our provision for income taxes is based on our current period income, changes in deferred income tax assets and liabilities, statutory income tax rates, changes in uncertain tax benefits and the deductibility of expenses or availability of tax credits in various taxing jurisdictions. Tax laws are complex, subject to different interpretations by the taxpayer and the respective governmental taxing authorities and are subject to future modification, expiration or repeal by government legislative bodies. We use significant judgment on a quarterly basis in determining our annual effective income tax rate and evaluating our tax positions. We regularly review our deferred tax assets for recoverability and establish a valuation allowance, if necessary, based on historical taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences. Although realization is not assured, management believes it is more likely than not that the recorded deferred tax assets, as adjusted for valuation allowances, will be realized. Additionally, deferred tax liabilities are regularly reviewed to confirm that such amounts are appropriately stated. A review of our deferred tax items considers known future changes in various income tax rates, principally in the United States. If income tax rates were to change in the future, particularly in the United States and to a lesser extent Canada, the U.K. and Italy, our items of deferred tax could be materially affected. All of such evaluations require significant management judgments. We record liabilities for an unrecognized tax benefit when a tax benefit for an uncertain tax position is taken or expected to be taken on a tax return, but is not recognized in our consolidated financial statements because it does not meet the more-likely-than-not recognition threshold that the uncertain tax position would be sustained upon examination by the applicable taxing authority. Any adjustments upon resolution of income tax uncertainties are recognized in our results of operations. Unrecognized tax benefits are analyzed periodically and adjustments are made as events occur to warrant adjustment to the related liability. Historically, we have not had significant unrecognized tax benefits. Newly Adopted Accounting Standards In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, “ Improvements to Employee Share-Based Payment Accounting ” (“ASU 2016-09”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements. The new guidance also requires that all tax-related cash flows resulting from share-based payments to be reported as operating activities in the statement of cash flows. We early adopted ASU 2016-09 on August 1, 2016, on a prospective basis. As a result, we no longer record excess tax benefits as an adjustment to additional paid-in capital, we record such excess tax benefits as a reduction of income tax expense, which amounted to $2,241 for the year ended July 31, 2017. See Note 11, "Income Taxes" and Note 15, "Stock-based Compensation." In addition, we elected to record excess tax benefits as an operating cash flow prospectively and not adjust the prior year period. As such, the current period excess tax benefits were reflected as an operating cash flow rather than a financing cash flow on our consolidated statement of cash flows for the year ended July 31, 2017. Furthermore, we have elected to account for forfeitures as they occur, rather than estimate expected forfeitures over the course of a vesting period since forfeitures have been insignificant historically. Recently Issued Accounting Standards In May 2017, the FASB issued ASU 2017-09, " Scope of Modification Accounting " ("ASU 2017-09") to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-12 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. We are currently in the process of evaluating the impact of ASU 2017-09 on our financial position and result of operations. In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”) to simplify the test for goodwill impairment. The revised guidance eliminates the existing Step 2 of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. Under the revised guidance, an entity would recognize an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to the reporting unit. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-04 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020) and early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a significant impact on our financial position and result of operations. In January 2017, the FASB issued ASU 2017-01, “ Business Combinations (Topic 805)” (“ASU 2017-01”) to clarify the definition of a business. The revised guidance creates a more robust framework to use in determining whether a set of assets and activities is a business. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. We are currently in the process of evaluating the impact of ASU 2017-01 on our financial position and result of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows” (“ASU 2016-15”). This new guidance will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019). ASU 2016-15 will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. We are currently in the process of evaluating the impact of ASU 2016-15 on our financial position and result of operations. In February 2016, FASB issued ASU 2016-02, “ Leases (Topic 842) ” (“ASU 2016-02”). The new guidance requires the recording of assets and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. The new guidance is expected to provide transparency of information and comparability among organizations. ASU 2016-02 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. We are currently in the process of evaluating the impact of ASU 2016-02 on our financial position and results of operations. In September 2015, the FASB issued ASU 2015-16, “ Simplifying the Accounting for Measurement-Period Adjustments (Topic 805)” (“ASU 2015-16”). The new guidance requires an acquirer in a business combination to recognize a measurement-period adjustment during the period in which it determines the amount, and eliminates the requirement for an acquirer to account for measurement-period adjustments retrospectively. The acquirer must also disclose the amounts and reasons for adjustments to the provisional amounts. ASU 2015-16 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we will adopt ASU 2015-06 in our first quarter of fiscal 2018. The adoption of ASU 2015-06 is not expected to have a material impact upon on our financial position and results of operations. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330) Simplifying the Measurement of Inventory,” (“ASU 2015-11”). The new guidance requires companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we will adopt ASU 2015-11 in our first quarter of fiscal 2018. The adoption of ASU 2015-11 is not expected to have a material impact upon on our financial position and results of operations. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”), which will supersede the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition” ("ASC 605"). ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606),” which defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2016-12”), which provided narrow scope improvements and practical expedients relating to ASU 2014-09. In preparation for our adoption of ASU 2014-09 and ASU 2016-12 on August 1, 2018, we are obtaining representative samples of contracts and other forms of agreements with our customers in the United States and international locations and plan to evaluate the provisions contained therein in light of the five-step model specified by the new guidance. We are also evaluating the impact of the new standard on certain common practices currently employed by us and by other health care manufacturers and service providers, such as multiple-element arrangements, deferred revenues, warranties, rebates and other pricing allowances. We anticipate adopting the standard using the modified retrospective method. There may be differences in timing of revenue recognition under the new standard compared to recognition under ASC 605.

Acquisitions

Acquisitions	12 Months Ended
	Jul. 31, 2017
Business Combinations [Abstract]
Acquisitions	Acquisitions Post-Fiscal 2017 BHT Group On August 23, 2017, we purchased all of the issued and outstanding stock of BHT Group, a leader in the German market in automated endoscope reprocessing and related equipment and services for total consideration, excluding acquisition related costs, of $61,236 . The BHT Group consists of a portfolio of high-quality automatic endoscope reprocessors, advanced endoscope storage and drying cabinets (products globally distributed by our Company prior to the acquisition under an agreement with BHT Group), washer-disinfectors for central sterile applications, associated technical service and parts as well as flexible endoscope repair services. BHT Group will be included in our Endoscopy segment. Fiscal 2017 CR Kennedy On April 1, 2017, we purchased certain endoscopy-related net assets of CR Kennedy related to its distribution and sale of our Medivators endoscopy products in Australia for total consideration, excluding acquisition related costs, of $11,999 . The CR Kennedy business includes a full sales and service organization and our Medivators-branded automated endoscope reprocessors, chemistries, endoscopy procedure products and other consumables in Australia, and is included in our Endoscopy segment. Vantage Endoscopy Inc.’s Medivators ® Endoscopy Business On September 26, 2016, we acquired certain net assets of Vantage related to its distribution and sale of our Medivators endoscopy products in Canada for total consideration, excluding acquisition-related costs, of $4,044 . Vantage was our exclusive distributor of Medivators capital equipment (e.g., automated endoscope reprocessors) and related consumables and accessories in Canada, and is included in our Endoscopy segment. Accutron, Inc. On August 1, 2016, we acquired all of the issued and outstanding stock of Accutron, a Phoenix-based company, for total consideration, excluding acquisition-related costs, of $53,049 . The Accutron business designs, manufactures and sells nitrous oxide conscious sedation equipment and single use nasal masks for use in dental procedures, and is included in our Healthcare Disposables segment. Fiscal 2016 North American Science Associates, Inc. On March 1, 2016, we acquired certain net assets of NAMSA for total consideration, excluding acquisition-related costs, of $13,424 . The NAMSA business manufactures a broad suite of high-quality biological and chemical indicators which are used to accurately monitor the effectiveness of sterilization processes primarily for manufacturers of medical device, life science and other products, and is included in our Healthcare Disposables segment. Medical Innovations Group Holdings Limited On September 14, 2015, we acquired all of the issued and outstanding stock of MI, a company providing specialized endoscopy medical devices and products primarily in the United Kingdom for total consideration, excluding acquisition-related costs, of $79,597 . The MI business includes proprietary short-term and long-term endoscope transport and storage systems, a comprehensive range of endoscopic consumable accessories, OEM mobile medical carts, as well as specialized products for patient warming and patient transfer, and is included in our Endoscopy segment. 2017 2016 Purchase Price Allocation CR Kennedy Vantage (1) Accutron (1) NAMSA (1) MI Purchase Price: Cash paid $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 Debt acquired — — — — — Total $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 Allocation: Property and equipment — 433 1,676 437 6,464 Amortizable intangible assets: Customer relationships 4,200 992 12,800 5,820 24,430 Technology — — 10,000 1,320 10,930 Brand names — — 2,000 — 2,030 Goodwill 5,894 2,299 21,989 3,687 40,006 Deferred income taxes — — 112 — (8,683 ) Other working capital 1,905 320 4,472 2,160 4,420 Total $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 _______________________________________________ (1) The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes. Unaudited Pro Forma Summary of Operations The acquisitions above, both individually and in the aggregate, were not material to our consolidated results of operations or financial position and, therefore, pro forma financial information is not presented.

Inventories, Net

Inventories, Net	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net A summary of inventories, net, is as follows: July 31, 2017 2016 Raw materials and parts $ 45,831 $ 45,867 Work-in-process 13,484 13,178 Finished goods 48,262 37,831 Less: reserve for excess and obsolete inventory (8,853 ) (5,390 ) Total $ 98,724 $ 91,486

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net A summary of property and equipment, net, is as follows: July 31, 2017 2016 Land, buildings and improvements $ 46,921 $ 44,387 Furniture and equipment 119,682 95,033 Leasehold improvements 7,858 6,048 Less: accumulated depreciation (86,123 ) (70,864 ) Total $ 88,338 $ 74,604

Derivatives

Derivatives	12 Months Ended
	Jul. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives We recognize all derivatives on the balance sheet at fair value. Derivatives that are not designated as hedges must be adjusted to fair value through earnings. If the derivative is designated as a hedge, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in the fair value of the hedged assets, liabilities or firm commitments through earnings or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of the change in fair value of a derivative that is designated as a hedge will be recognized immediately in earnings. As of July 31, 2017 , all of our derivatives were designated as hedges. We do not hold any derivative financial instruments for speculative or trading purposes. Changes in the value of the Euro, British Pound, Singapore dollar, Canadian dollar, Australian dollar and the Chinese Renminbi against the U.S. dollar affect our results of operations because certain cash bank accounts, accounts receivable, and liabilities of Cantel and its subsidiaries are denominated and ultimately settled in U.S. dollars or these foreign currencies, but must be converted into each entity’s functional currency. In order to hedge against the impact of fluctuations in the value of the Euro, British Pound, Canadian dollar, Australian dollar and Singapore dollar relative to the U.S. dollar on the conversion of such net assets into the functional currencies, we enter into short-term contracts to purchase Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars forward, which contracts are one -month in duration. These short-term contracts are designated as fair value hedge instruments. There were nine foreign currency forward contracts with an aggregate notional value of $24,762 at July 31, 2017 , which covered certain assets and liabilities that were denominated in currencies other than each entity’s functional currency. These foreign currency forward contracts are continually replaced with new one -month contracts as long as we have significant net assets that are denominated and ultimately settled in currencies other than each entity’s functional currency. For the fiscal year ended July 31, 2017 , such forward contracts partially offset the impact on operations relating to certain assets and liabilities that were denominated in currencies other than each entity’s functional currency. This resulted in an immaterial amount of net currency conversion losses, net of tax, on the hedged items. Gains and losses related to hedging contracts to buy Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars forward are immediately realized within general and administrative expenses due to the short-term nature of such contracts. We do not currently hedge against the impact of fluctuations in the value of the Chinese Renminbi relative to the U.S. dollar because the overall foreign currency exposures relating to those currencies are currently not deemed significant.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jul. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair Value Hierarchy We apply the provisions of Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. We define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three level fair value hierarchy to prioritize the inputs used in valuations, as defined below: Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities in active markets. Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs for the asset or liability. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Our financial assets that are re-measured at fair value on a recurring basis include money market funds that are classified as cash and cash equivalents in the consolidated balance sheets. These money market funds are classified within Level 1 of the fair value hierarchy and are valued using quoted market prices for identical assets. In connection with our June 2014 acquisition of a U.K. endoscopy company (“Cantel Medical (U.K.)”), we acquired a contingent guaranteed obligation to reimburse an endoscope service company for endoscope repair costs it incurs when servicing its customers’ endoscopes that are damaged by one of Cantel Medical (U.K.)’s discontinued endoscope reprocessing machine models. The fair value of the contingent liability was $441 as of July 31, 2016. This liability continued to be adjusted periodically by the reimbursement of repair costs, as well as adjustments associated with changes in the fair value through our consolidated statements of income. During the third quarter of fiscal 2017, we ended the agreement with the endoscopy service company and decreased this liability to $0 at July 31, 2017. In connection with the Jet Prep Ltd. ("Jet Prep") acquisition in fiscal 2014, we assumed a contingent obligation payable to the Israeli Government based on future sales. This fair value measurement was based on significant inputs not observed in the market and thus represent Level 3 measurements. As a result of the exit of the Jet Prep business, we did not update our fair value assumptions associated with this contingent obligation payable and the balance of such obligation remained at $1,138 as of July 31, 2017. See Note 8, "Intangibles and Goodwill." The fair values of the Company’s financial instruments measured on a recurring basis were categorized as follows: July 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 102 $ — $ — $ 102 Total assets 102 — — 102 Liabilities: Accrued expenses: Assumed contingent obligation — — 12 12 Contingent guaranteed obligation — — — — Total accrued expenses — — 12 12 Long-term debt (1) — 126,000 — 126,000 Other long-term liabilities: Assumed contingent obligation — — 1,126 1,126 Contingent guaranteed obligation — — — — Total other long-term liabilities: — — 1,126 1,126 Total liabilities $ — $ 126,000 $ 1,138 $ 127,138 ________________________________________________ (1) Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active. July 31, 2016 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 740 $ — $ — $ 740 Total assets $ 740 $ — $ — $ 740 Liabilities: Accrued expenses: Assumed contingent obligation — — 12 12 Contingent guaranteed obligation — — 366 366 Total accrued expenses — — 378 378 Long-term debt (1) — 116,000 — 116,000 Other long-term liabilities: Contingent consideration — — — — Assumed contingent obligation — — 1,126 1,126 Contingent guaranteed obligation — — 75 75 Total other long-term liabilities: — — 1,201 1,201 Total liabilities $ — $ 116,000 $ 1,579 $ 117,579 ________________________________________________ (1) Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active. A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) for fiscal 2017 , 2016 and 2015 is as follows: Jet Prep Contingent Consideration Jet Prep Assumed Contingent Obligation Cantel Medical (U.K.) Contingent Guaranteed Obligation Total Balance, July 31, 2014 $ 2,722 $ 1,752 $ 1,395 $ 5,869 Total net unrealized gains included in general and administrative expense in earnings (1,971 ) (614 ) — (2,585 ) Net purchases, issuances, sales and settlements — — (507 ) (507 ) Balance, July 31, 2015 751 1,138 888 2,777 Total net unrealized (gains) losses included in general and administrative expense in earnings (751 ) — 64 (687 ) Net purchases, issuances, sales and settlements — — (511 ) (511 ) Balance, July 31, 2016 — 1,138 441 1,579 Total net unrealized gains included in general and administrative expense in earnings — — (265 ) (265 ) Net purchases, issuances, sales and settlements — — (176 ) (176 ) Balance, July 31, 2017 $ — $ 1,138 $ — $ 1,138 Disclosure of Fair Value of Financial Instruments As of July 31, 2017 and 2016 , the carrying amounts for cash and cash equivalents (excluding money markets), accounts receivable and accounts payable approximated fair value due to the short maturity of these instruments.

Intangibles and Goodwill

Intangibles and Goodwill	12 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Goodwill	Intangibles and Goodwill Our intangible assets with definite lives consist primarily of customer relationships, technology, brand names, non-compete agreements and patents. These intangible assets are being amortized on the straight-line method over the estimated useful lives of the assets ranging from 3 - 20 years and have a weighted average amortization period of 12 years . Amortization expense related to intangible assets was $18,407 , $13,095 and $13,265 for fiscal 2017 , 2016 and 2015 , respectively. Our intangible assets that have indefinite useful lives, and therefore are not amortized, consist of trademarks and trade names. The Company’s intangible assets consist of the following: July 31, 2017 July 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships $ 119,576 $ (34,773 ) $ 84,803 $ 100,649 $ (24,689 ) $ 75,960 Technology 42,794 (18,990 ) 23,804 32,767 (11,813 ) 20,954 Brand names 8,188 (3,225 ) 4,963 6,194 (2,394 ) 3,800 Non-compete agreements 3,092 (1,428 ) 1,664 3,092 (1,193 ) 1,899 Patents and other registrations 2,783 (1,053 ) 1,730 2,508 (913 ) 1,595 176,433 (59,469 ) 116,964 145,210 (41,002 ) 104,208 Trademarks and tradenames 7,548 — 7,548 7,511 — 7,511 Total intangible assets $ 183,981 $ (59,469 ) $ 124,512 $ 152,721 $ (41,002 ) $ 111,719 During fiscal 2017, we decided to exit the Jet Prep business that was acquired in fiscal 2014. The Jet Prep acquisition was a fully integrated business within our Endoscopy segment. The useful life of the technology related intangible asset was revised to its respective cease use date, which resulted in accelerated amortization of approximately $2,401 that was recorded in the consolidated statements of income. In addition, we performed a relative fair value analysis for the goodwill recorded as part of the Jet Prep acquisition and determined that all of the goodwill would remain within the Endoscopy segment. We performed our annual goodwill impairment test of all of our reportable segments as of July 31, 2017, including the Endoscopy segment, which did not result in any impairment of our goodwill. We expect to recognize $15,617 , $15,293 , $13,539 , $13,204 and $12,821 of amortization expense related to intangible assets in fiscal years 2018 , 2019 , 2020 , 2021 and 2022 , respectively. Goodwill changed during fiscal 2017 and 2016 as follows: Endoscopy Water Purification and Filtration Healthcare Disposables Dialysis Total Goodwill Balance, July 31, 2015 $ 87,007 $ 58,872 $ 87,939 $ 8,133 $ 241,951 Acquisitions 40,047 — 4,351 — 44,398 Foreign currency translation (6,039 ) 8 — — (6,031 ) Balance, July 31, 2016 121,015 58,880 92,290 8,133 280,318 Acquisitions 8,193 — 21,989 — 30,182 Foreign currency translation 737 208 — — 945 Balance, July 31, 2017 $ 129,945 $ 59,088 $ 114,279 $ 8,133 $ 311,445 On July 31, 2017 , we performed impairment analysis of the Company’s goodwill and indefinite lived trademarks and trade names and concluded that such assets were not impaired, as more fully described in Note 2, "Summary of Significant Accounting Policies." In fiscal 2014, we acquired a license from a third party granting us the exclusive right to manufacture, commercialize, distribute and sell an endoscopy product in exchange for a series of payments, which totaled $1,000 at January 31, 2015 and was recorded in other assets in our consolidated balance sheets. We evaluated this long-lived asset for potential impairment and determined that the future use of this acquired license was unlikely based on a recent product analysis. Accordingly, we deemed the acquired license, together with related fixed assets, to be fully impaired and recorded a loss of $1,287 during fiscal 2015 based on expected cash flows of the related endoscopy product, which was recorded in general and administrative expenses and as reductions in other assets and property and equipment in the consolidated financial statements.

Warranties

Warranties	12 Months Ended
	Jul. 31, 2017
Product Warranties Disclosures [Abstract]
Warranties	Warranties A summary of activity in the warranty reserves follows: Year Ended July 31, 2017 2016 Beginning balance $ 2,575 $ 1,740 Acquisitions 179 28 Provisions 4,880 4,554 Settlements (5,306 ) (3,622 ) Foreign currency translation — (125 ) Ending balance $ 2,328 $ 2,575 The warranty provisions and settlements in fiscal 2017 and 2016 relate principally to the Company’s endoscope reprocessing and water purification products. Warranty reserves are included in accrued expenses in the consolidated balance sheets.

Financing Arrangements

Financing Arrangements	12 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements On March 4, 2014, we entered into a Third Amended and Restated Credit Agreement (the “2014 Credit Agreement”). The 2014 Credit Agreement includes a five -year $250,000 senior secured revolving facility with sublimits of up to $100,000 for borrowings in foreign currencies, $30,000 for letters of credit and $10,000 for swing line loans (the “2014 Revolving Credit Facility”). Subject to the satisfaction of certain conditions precedent including the consent of the lenders, the Company may from time to time increase the 2014 Revolving Credit Facility by an aggregate amount not to exceed $100,000 . The 2014 Credit Agreement expires on March 4, 2019. Additionally, subject to certain restrictions and conditions (i) any of our domestic or foreign subsidiaries may become borrowers and (ii) borrowings may occur in multi-currencies. Borrowings under the 2014 Credit Agreement bear interest at rates ranging from 0.25% to 1.25% above the lender’s base rate, or at rates ranging from 1.25% to 2.25% above the London Interbank Offered Rate (“LIBOR”), depending upon the Company’s “Consolidated Leverage Ratio,” which is defined as the consolidated ratio of total funded debt to earnings before interest, taxes, depreciation and amortization, and as further adjusted under the terms of the 2014 Credit Agreement (“Consolidated EBITDA”). At July 31, 2017 , the lender’s base rate was 4.00% and the LIBOR rates ranged from 1.22% to 1.31% . The margins applicable to our outstanding borrowings were 0.50% above the lender’s base rate or 1.50% above LIBOR. All of our outstanding borrowings were under LIBOR contracts at July 31, 2017 . The 2014 Credit Agreement also provides for fees on the unused portion of our facility at rates ranging from 0.20% to 0.40% , depending upon our Consolidated Leverage Ratio, which was 0.20% at July 31, 2017 . The 2014 Credit Agreement contains affirmative and negative covenants reasonably customary for similar credit facilities and is secured by (i) substantially all assets of Cantel and its U.S.-based subsidiaries, (ii) a pledge by Cantel of all of the outstanding shares of its U.S.-based subsidiaries and 65% of the outstanding shares of certain of Cantel’s foreign-based subsidiaries and (iii) a guaranty by Cantel’s domestic subsidiaries. We are in compliance with all financial and other covenants under the 2014 Credit Agreement. As of July 31, 2017 , we had $126,000 of outstanding borrowings under the 2014 Credit Agreement. Subsequent to July 31, 2017 , we borrowed $61,300 to fund the purchase price and transaction costs of the BHT Group acquisition. Debt issuance costs associated with our credit facilities are capitalized and amortized to interest expense over the term of the credit facilities. As of July 31, 2017 and 2016 , such debt issuance costs, net of related amortization, were included in other assets, and amounted to $580 and $946 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The consolidated effective tax rate was 32.8% , 36.2% and 37.1% for fiscal 2017 , 2016 and 2015 , respectively, and reflects income tax expense for our U.S. and international operations at their respective statutory rates. The provision for income taxes consists of the following: Year Ended July 31, 2017 2016 2015 Current Deferred Current Deferred Current Deferred United States: Federal $ 28,900 $ 2,020 $ 29,392 $ (216 ) $ 24,602 $ (425 ) State 4,352 261 4,433 (153 ) 3,920 (218 ) International 1,545 (2,223 ) 1,863 (1,341 ) 1,165 (806 ) Total $ 34,797 $ 58 $ 35,688 $ (1,710 ) $ 29,687 $ (1,449 ) The geographic components of income before income taxes are as follows: Year Ended July 31, 2017 2016 2015 United States $ 108,329 $ 92,744 $ 73,645 International (2,096 ) 1,187 2,546 Total $ 106,233 $ 93,931 $ 76,191 The consolidated effective income tax rate differed from the U.S. statutory tax rate of 35.0% in fiscal 2017 , 2016 and 2015 due to the following: Year Ended July 31, 2017 2016 2015 Expected statutory tax 35.0 % 35.0 % 35.0 % Differential attributable to: Foreign operations — % 0.6 % 1.2 % State and local taxes 3.9 % 3.2 % 3.4 % Domestic production deduction (2.7 )% (2.3 )% (2.4 )% Acquisition related items, net 0.1 % — % (1.6 )% Loss on sale of business — % — % 1.1 % R&E tax credit (1.4 )% (1.1 )% (0.5 )% Change in foreign tax rates — % (0.4 )% — % Excess tax benefits (2.2 )% — % — % Other 0.1 % 1.2 % 0.9 % Consolidated effective tax rate 32.8 % 36.2 % 37.1 % As a result of the adoption of ASU 2016-09 on August 1, 2016, we no longer record excess tax benefits as an adjustment to additional paid-in-capital, but record such excess tax benefits on a prospective basis as a reduction of income tax expense, which amounted to $2,241 for fiscal 2017. Deferred income tax assets and liabilities are comprised of the following: July 31, 2017 2016 Deferred tax assets: Accrued expenses $ 6,308 $ 5,140 Inventories 4,655 2,990 Accounts receivable 729 793 Other long-term liabilities 180 252 Stock-based compensation 3,402 3,665 Capital investment 545 546 Foreign NOLs 6,490 5,154 Subtotal 22,309 18,540 Valuation allowance (2,984 ) (2,334 ) 19,325 16,206 Deferred tax liabilities: Property and equipment (9,957 ) (8,089 ) Intangible assets (20,107 ) (19,818 ) Goodwill (13,975 ) (11,878 ) (44,039 ) (39,785 ) Net deferred tax liabilities - noncurrent $ (24,714 ) $ (23,579 ) For foreign tax reporting purposes, our Net Operating Losses (“NOLs”) at July 31, 2017 are $6,490 and originated primarily from foreign acquisitions. Most of these NOLs do not expire and are fully available for utilization against future profits in certain non-U.S. tax jurisdictions. However, we have recorded a valuation allowance of $2,984 for these foreign NOLs, which are primarily associated with certain early-stage foreign operations as well as the exit of the Jet Prep business more fully described in Note 8, "Intangibles and Goodwill." We believe it is more likely than not that we will be unable to utilize these NOLs. During fiscal 2017 and 2016 , no dividends were repatriated from our foreign subsidiaries. All of the undistributed earnings of our foreign subsidiaries are considered to be indefinitely reinvested at July 31, 2017 . Accordingly, deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. At July 31, 2017 , the cumulative amount of such undistributed earnings indefinitely reinvested outside the United States was approximately $44,509 . Determining the tax liability that would arise if these earnings were remitted is not practical. We record liabilities for an unrecognized tax benefit when a tax benefit for an uncertain tax position is taken or expected to be taken on a tax return, but is not recognized in our consolidated financial statements because it does not meet the more-likely-than-not recognition threshold that the uncertain tax position would be sustained upon examination by the applicable taxing authority. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon settlement with the tax authorities. Any adjustments upon resolution of income tax uncertainties are recognized in our results of operations. Our policy is to record potential interest and penalties related to income tax positions in interest expense and general and administrative expense, respectively, in our consolidated financial statements. However, such amounts have been relatively insignificant due to the nominal amount of our unrecognized tax benefits relating to uncertain tax positions. The Company concluded an audit by the Internal Revenue Service (“IRS”) for fiscal years 2015, 2013 and 2012. With respect to state or foreign income tax examinations, the Company is generally no longer subject to examinations for fiscal years ended prior to July 31, 2009.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases We have several non-cancelable operating leases, primarily for our corporate headquarters, certain of our leased manufacturing facilities, warehouses, office space and equipment. Total rental expense related to our operating leases was $7,715 , $6,675 and $6,025 for fiscal 2017, 2016 and 2015 , respectively. As of July 31, 2017, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) for the periods set forth below were as follows: Fiscal year ending: Total 2018 $ 6,522 2019 5,278 2020 3,779 2021 2,719 2022 1,231 Thereafter 2,454 Total $ 21,983 Contingent Consideration and Assumed Contingent Liability We have $1,138 recorded as of July 31, 2017 related to the Jet Prep acquisition, which is for the estimated fair value of an assumed contingent obligation payable to the Israeli Government, as further described in Note 8, "Intangibles and Goodwill," which will be payable based on future sales. We are currently working with the Israeli Government to forgive any future amounts payable due to our decision to exit the Jet Prep business and we expect a decision from the Israeli government in the first half of fiscal 2018. Additionally, in connection with the PuriCore plc acquisition in fiscal 2014, we assumed a contingent guaranteed obligation to reimburse an endoscope service company for endoscope repair costs it incurs when servicing its customers’ endoscopes that are damaged by one of PuriCore’s discontinued endoscope reprocessing machine models. During fiscal 2017, we ended the agreement with the endoscope service company and decreased the remaining liability of $283 through our consolidated statements of income. Legal Proceedings In the normal course of business, we are subject to pending and threatened legal actions. It is our policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount of anticipated exposure can be reasonably estimated. We do not believe that any of these pending claims or legal actions will have a material effect on our business, financial condition, results of operations or cash flows.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Jul. 31, 2017
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The components and changes in accumulated other comprehensive loss for fiscal 2017 , 2016 and 2015 were as follows: Foreign Currency Translation Adjustments Balance, July 31, 2014 $ 9,552 Other comprehensive loss before reclassification adjustments (7,064 ) Reclassification adjustment to loss on sale of business for foreign currency translation gain included in net income during the year (1,264 ) Balance, July 31, 2015 1,224 Other comprehensive loss (13,019 ) Balance, July 31, 2016 (11,795 ) Other comprehensive income 1,895 Balance, July 31, 2017 $ (9,900 )

Earnings Per Common Share

Earnings Per Common Share	12 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Common Share	Earnings Per Common Share Basic EPS is computed based upon the weighted average number of common shares outstanding for the year. Diluted EPS is computed based upon the weighted average number of common shares outstanding for the year plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the year. We include participating securities (unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents) in the computation of EPS pursuant to the two-class method. Our participating securities consist solely of unvested restricted stock awards, which have contractual participation rights equivalent to those of stockholders of unrestricted common stock. The two-class method of computing earnings per share is an allocation method that calculates earnings per share for common stock and participating securities. The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities): Year Ended July 31, 2017 2016 2015 Numerator for basic and diluted earnings per share: Net income $ 71,378 $ 59,953 $ 47,953 Less income allocated to participating securities (431 ) (488 ) (433 ) Net income available to common shareholders $ 70,947 $ 59,465 $ 47,520 Denominator for basic and diluted earnings per share, as adjusted for participating securities: Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock 41,468,487 41,344,013 41,139,467 Dilutive effect of stock options using the treasury stock method and the average market price for the year 74,278 46,181 63,133 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,542,765 41,390,194 41,202,600 Earnings per share attributable to common stock: Basic earnings per share $ 1.71 $ 1.44 $ 1.16 Diluted earnings per share $ 1.71 $ 1.44 $ 1.15 Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive — — — A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to the Company’s total weighted average number of shares and common stock equivalents, including participating securities, is set forth in the following table: Year Ended July 31, 2017 2016 2015 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,542,765 41,390,194 41,202,600 Participating securities 254,727 340,363 378,706 Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities 41,797,492 41,730,557 41,581,306

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation 2016 Equity Incentive Plan On January 7, 2016, the Company terminated the Cantel Medical Corp. 2006 Equity Incentive Plan (the “2006 Plan”) and adopted the Cantel Medical Corp. 2016 Equity Incentive Plan (the “2016 Plan”). As a result, no further options or awards will be granted under the Cantel Medical Corp. 2006 Equity Incentive Plan. The 2016 Plan provides for the granting of stock options, stock appreciation rights (SARs), restricted stock awards, restricted stock units (RSUs) and performance-based awards to our employees, independent contractors and consultants. It also provides the flexibility to grant equity-based awards to our non-employee directors. The 2016 Plan does not permit the granting of discounted options or discounted stock appreciation rights. The maximum number of shares as to which equity awards may be granted under the 2016 Plan is 1,200,000 shares. The 2016 Plan will terminate on the date of our annual meeting of stockholders following the close of our fiscal year ending in 2025, unless terminated earlier by the Board of Directors. Stock awards under this plan: • will be granted at the closing market price at the time of the grant, • will include terms which may not exceed ten years, subject to certain exceptions set forth in the Plan, and • may be granted in the form of Restricted Stock and Restricted Stock Units, Performance Awards, or Dividends. Stock awards outstanding under this plan are subject to risk of forfeiture solely due to an employment length-of-service restriction, with such restriction lapsing as to one-third of the shares of each of the first three anniversaries of the grant date subject to being employed by the Company through such vesting date. At July 31, 2017 , 113,926 unvested restricted stock shares were outstanding under the 2016 plan. No options were outstanding under the 2016 plan. At July 31, 2017 , 1,086,911 shares are collectively available pursuant to restricted stock and other stock awards and stock options and stock appreciation rights. 2006 Equity Incentive Plan A total of 5,591,000 shares of common stock, of which 2,700,000 shares were authorized for issuance pursuant to stock options and stock appreciation rights and 2,891,000 shares were authorized for issuance pursuant to restricted stock and other stock awards under the 2006 Plan, which was terminated on January 7, 2016 in conjunction with the adoption of the 2016 Plan. Restricted stock shares outstanding under this plan are subject to risk of forfeiture solely due to an employment length-of-service restriction, with such restriction lapsing as to one-third of the shares on each of the first three anniversaries of the grant date subject to being employed by the Company through such vesting date. At July 31, 2017 , options to purchase 122,500 shares of common stock were outstanding, and 108,372 unvested restricted stock shares were outstanding under the 2006 Plan. No additional awards will be granted under this plan. The following table shows the income statement components of stock-based compensation expense recognized in the consolidated statements of income: Year Ended July 31, 2017 2016 2015 Cost of sales $ 371 $ 438 $ 270 Operating expenses: Selling 1,582 929 608 General and administrative 6,774 6,881 4,897 Research and development 117 113 92 Total operating expenses 8,473 7,923 5,597 Stock-based compensation before income taxes $ 8,844 $ 8,361 $ 5,867 Our stock options and time-based stock awards are subject to graded vesting in which portions of the awards vest at different times during the vesting period. We recognize compensation expense for awards subject to graded vesting using the straight-line basis over the vesting period. In October 2016, we granted for the first time to certain employees both equity awards with performance conditions and equity awards with market conditions. The actual number of equity awards earned and eligible to vest will be determined based on the level of achievement against budgeted revenue and a defined gross profit percentage, with respect to the awards with performance conditions, and the Company’s 3-year relative total stockholder return performance as measured against the S&P Healthcare Equipment Index, with respect to the awards with market conditions. The maximum share attainment of these awards are 200% of the initial granted shares. We recognize compensation expense for the awards with performance conditions using the accelerated attribution method over the requisite service period for each separately vesting portion of the award when it is probable that the performance condition will be achieved. We record expense for the awards that are subject to market conditions ratably over the vesting period regardless of whether the market condition is satisfied. At July 31, 2017 , total unrecognized stock-based compensation expense, before income taxes, related to total nonvested stock options and restricted stock awards was $9,741 with a remaining weighted average period of 17 months over which such expense is expected to be recognized. The majority of our nonvested awards relate to restricted stock awards. As a result of the adoption of ASU 2016-09 on August 1, 2016, we have elected to account for forfeitures as they occur, rather than estimate expected forfeitures over the vesting period. We determine the fair value of each time-based stock award and performance-based stock award by using the closing market price of our common stock on the date of grant. We determine the fair value of each stock award with market conditions using the Monte Carlo simulation on the date of grant using the following assumptions: Year Ended July 31, 2017 Volatility of common stock 27.75 % Average volatility of peer companies 32.98 % Average correlation coefficient of peer companies 35.35 % Risk-free interest rate 0.96 % A summary of nonvested stock award activity for the year ended July 31, 2017 follows: Number of Time-based Shares Number of Performance-based Shares Number of Market-based Shares Number of Total Shares Weighted Average Fair Value July 31, 2014 525,842 — — 525,842 $ 22.25 Granted 144,278 — — 144,278 $ 39.77 Vested (1) (313,797 ) — — (313,797 ) $ 18.62 Forfeited (12,804 ) — — (12,804 ) $ 26.20 July 31, 2015 343,519 — — 343,519 $ 32.77 Granted 175,700 — — 175,700 $ 55.40 Vested (1) (183,045 ) — — (183,045 ) $ 30.06 Forfeited (4,807 ) — — (4,807 ) $ 45.06 July 31, 2016 331,367 — — 331,367 $ 46.09 Granted 86,305 16,960 9,800 113,065 $ 81.77 Vested (1) (214,932 ) (725 ) (555 ) (216,212 ) $ 43.62 Forfeited (5,922 ) — — (5,922 ) $ 59.40 July 31, 2017 196,818 16,235 9,245 222,298 $ 66.28 _______________________________________________ (1) The aggregate fair value of all nonvested stock awards which vested was approximately $9,431 , $5,503 and $5,844 in fiscal 2017 , 2016 and 2015 , respectively. There were no options granted during the fiscal year ended July 31, 2017. The fair value of each option grant in the prior years was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended Year Ended July 31, 2016 July 31, 2015 Dividend yield 0.22 % 0.25 % Expected volatility (1) 55.90 % 33.90 % Risk-free interest rate (2) 1.41 % 1.55 % Expected lives (in years) (3) 5.00 5.00 ________________________________________________ (1) Volatility was based on historical closing prices of our common stock. (2) The U.S. Treasury rate based on the expected life at the date of grant. (3) Based on historical exercise behavior. A summary of stock option activity for the year ended July 31, 2017 follows: Number of shares Weighted Average Exercise Price Weighted Average Contractual Life Remaining (Years) Aggregate Intrinsic Value Outstanding at July 31, 2016 122,500 $ 29.36 Granted — — Exercised — — Outstanding at July 31, 2017 122,500 $ 29.36 1.27 $ 5,493 Exercisable at July 31, 2017 104,167 $ 26.28 1.02 $ 4,992 In fiscal 2017, 2016 and 2015, 23,333 , 35,834 and 27,500 , respectively, options vested, with an aggregate fair value of approximately $349 , $344 and $248 , respectively. There were no option grants and no options were exercised during fiscal 2017 . The weighted average fair value of options granted was $26.49 and $11.54 in fiscal 2016 and 2015 , respectively. At July 31, 2017 , 2016 and 2015, there were 122,500 , 122,500 and 107,500 , respectively, outstanding options with an aggregate fair value of $5,493 , $4,605 and $3,133 , respectively. As of July 31, 2017 and 2016 , all of the outstanding options had vested or were expected to vest in future periods. The Company does not currently have a publicly announced stock repurchase program. All of the shares purchased during fiscal 2017 and 2016 represent shares surrendered to the Company relating to cashless exercises of stock options and to pay employee withholding taxes due upon the vesting of restricted stock or the exercise of stock options. In fiscal 2017 and 2016 , such purchases amounted to 89,607 and 67,038 shares at a total average price per share of $77.12 and $55.68 , respectively. Upon exercise of stock options or grant of stock awards, we typically issue new shares of our common stock as opposed to using treasury shares. Additionally, all options were considered to be deductible for tax purposes in the valuation model. Such non-qualified options were tax-effected using the Company’s estimated U.S. effective tax rate at the time of grant. All of our stock options and restricted stock awards are expected to be deductible for tax purposes, except for certain stock awards granted to employees residing outside of the United States, and were tax-effected using the Company’s estimated U.S. effective tax rate at the time of grant. Excess tax benefits arise when the ultimate tax effect of the deduction for tax purposes is greater than the income tax benefit on stock-based compensation described above. Prior to the adoption of ASU 2016-09 on August 1, 2016, the differences noted above between actual tax deductions and the previously recorded deferred income tax assets were recorded as additional paid-in capital. For the year ended July 31, 2016 , income tax deductions of $3,059 were generated, of which $1,880 were recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefits of $1,179 were recorded as an increase to additional paid-in capital. As a result of the adoption of ASU 2016-09, we no longer record excess tax benefits as an adjustment to additional paid-in capital, but record such excess tax benefits prospectively as a reduction of income tax expense. For the year ended July 31, 2017 , income tax deductions of $5,592 were generated, of which $3,351 were previously recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefit of $2,241 was recorded as a reduction in income tax expense.

Retirement Plans

Retirement Plans	12 Months Ended
	Jul. 31, 2017
Retirement Benefits [Abstract]
Retirement Plans	Retirement Plans We have 401(k) Savings and Retirement Plans for the benefit of eligible U.S. employees. Additionally, our Canadian and certain European subsidiaries maintain profit sharing plans for the benefit of eligible employees. Contributions by the Company are both discretionary and non-discretionary and are limited in any year to the amount allowable by government tax authorities. Aggregate employer contributions recognized under these plans were $3,863 , $3,406 and $2,541 for fiscal 2017 , 2016 and 2015 , respectively.

Information as to Reportable Se

Information as to Reportable Segments and Foreign and Domestic Operations	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Information as to Reportable Segments and Foreign and Domestic Operations	Information as to Reportable Segments and Foreign and Domestic Operations In accordance with FASB ASC Topic 280, “ Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and operating income. None of our customers accounted for 10% or more of our consolidated net sales during fiscal 2017 , 2016 and 2015 . The Company’s reportable segments are as follows: Endoscopy: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products. Water Purification and Filtration: designs, develops, manufactures, sells, and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers, who collectively accounted for approximately 50.2% of our Water Purification and Filtration segment net sales in fiscal 2017 . Healthcare Disposables: designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. Three customers, who collectively accounted for approximately 43.4% of our Healthcare Disposables segment net sales in fiscal 2017 . Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Two customers collectively accounted for approximately 44.2% of our Dialysis segment net sales in fiscal 2017 . Other: On April 7, 2015, we completed the sale of our Specialty Packaging business and recorded a $2,206 loss associated with this divestiture, which is included in our consolidated statements of income in fiscal 2015. The operating results of the Specialty Packaging business through April 7, 2015 are reported in Other in the tables below. The results were not significant in relation to our overall consolidated operating results and did not have a major effect on our operations and financial results, and accordingly, has not been classified as a discontinued operation for any of the periods presented. Information as to reportable segments is summarized below: Year Ended July 31, 2017 2016 2015 Net sales: Endoscopy $ 398,773 $ 341,752 $ 248,654 Water Purification and Filtration 196,446 177,669 173,834 Healthcare Disposables 144,457 112,584 106,920 Dialysis 30,481 32,750 31,240 Other — — 4,356 Total $ 770,157 $ 664,755 $ 565,004 Year Ended July 31, 2017 2016 2015 Operating income: Endoscopy $ 73,440 $ 61,021 $ 40,863 Water Purification and Filtration 33,159 30,620 30,606 Healthcare Disposables 28,000 24,486 19,904 Dialysis 8,154 7,907 6,749 Other — — 1,118 142,753 124,034 99,240 General corporate expenses 32,343 26,783 18,479 Income from operations 110,410 97,251 80,761 Interest expense, net 4,303 3,320 2,364 Other income (126 ) — — Loss on sale of business — — 2,206 Income before income taxes $ 106,233 $ 93,931 $ 76,191 Year Ended July, 31 2017 2016 2015 Identifiable assets: Endoscopy $ 368,820 $ 347,107 $ 238,799 Water Purification and Filtration 147,477 137,731 138,069 Healthcare Disposables 208,328 157,918 145,391 Dialysis 17,211 20,147 26,452 General corporate, including cash and cash equivalents 44,537 31,629 35,320 Total $ 786,373 $ 694,532 $ 584,031 Year Ended July, 31 2017 2016 2015 Capital expenditures: Endoscopy $ 13,816 $ 11,299 $ 7,042 Water Purification and Filtration 3,689 3,376 2,984 Healthcare Disposables 2,492 2,606 1,587 Dialysis 1,296 667 894 Other — — 19 General corporate 5,772 941 234 Total $ 27,065 18,889 12,760 Year Ended July, 31 2017 2016 2015 Depreciation and amortization: Endoscopy $ 18,245 $ 14,333 $ 10,729 Water Purification and Filtration 5,706 5,441 5,257 Healthcare Disposables 8,556 4,361 6,354 Dialysis 427 681 1,382 Other — — 78 General corporate 518 268 157 Total $ 33,452 $ 25,084 $ 23,957 Information as to geographic areas (including net sales which represent the geographic area from which the Company derives its net sales from external customers) is summarized below: Year Ended July, 31 2017 2016 2015 Net sales: United States $ 599,657 $ 515,055 $ 447,848 Europe/Africa/Middle East 95,753 88,355 62,193 Asia/Pacific 40,964 33,374 28,529 Canada 26,648 20,975 19,306 Latin America/South America 7,135 6,996 7,128 Total $ 770,157 $ 664,755 $ 565,004 July 31, 2017 2016 2015 Total long-lived assets: United States $ 74,401 $ 62,820 $ 57,080 Europe/Africa/Middle East 16,209 14,863 9,122 Asia/Pacific 1,381 1,607 1,081 Canada 1,054 463 600 Total 93,045 79,753 67,883 Goodwill and intangible assets, net 435,957 392,037 327,787 Total $ 529,002 $ 471,790 $ 395,670

Quarterly Results of Operations

Quarterly Results of Operations (unaudited)	12 Months Ended
	Jul. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations (unaudited)	Quarterly Results of Operations (unaudited) The following is a summary of the quarterly results of operations for the years ended July 31, 2017 and 2016 : 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 187,725 $ 184,817 $ 192,113 $ 205,502 Cost of sales 98,218 96,340 100,665 107,774 Gross profit 89,507 88,477 91,448 97,728 Gross profit percentage 47.7 % 47.9 % 47.6 % 47.6 % Net income $ 18,800 $ 18,070 $ 17,511 $ 16,997 Earnings per common share: Basic $ 0.45 $ 0.43 $ 0.42 $ 0.41 Diluted $ 0.45 $ 0.43 $ 0.42 $ 0.41 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 153,779 $ 158,271 $ 173,703 $ 179,002 Cost of sales 82,581 85,934 93,382 93,672 Gross profit 71,198 72,337 80,321 85,330 Gross profit percentage 46.3 % 45.7 % 46.2 % 47.7 % Net income $ 14,254 $ 15,389 $ 14,019 $ 16,291 Earnings per common share: Basic $ 0.34 $ 0.37 $ 0.34 $ 0.39 Diluted $ 0.34 $ 0.37 $ 0.34 $ 0.39

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Jul. 31, 2017
Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	Schedule II - Valuation and Qualifying Accounts Balance at Beginning of Period Additions Deductions Translation Adjustments Balance at End of Period Allowance for doubtful accounts: Year ended July 31, 2017 $ 1,850 $ 998 $ (1,056 ) $ 16 $ 1,808 Year ended July 31, 2016 $ 2,092 $ 15 $ (223 ) $ (34 ) $ 1,850 Year ended July 31, 2015 $ 1,874 $ 464 $ (227 ) $ (19 ) $ 2,092 Reserve for excess and obsolete inventory: Year ended July 31, 2017 $ 5,390 $ 5,016 $ (1,580 ) $ 27 $ 8,853 Year ended July 31, 2016 $ 3,895 $ 3,182 $ (1,569 ) $ (118 ) $ 5,390 Year ended July 31, 2015 $ 4,419 $ 1,494 $ (1,796 ) $ (222 ) $ 3,895 Deferred tax asset valuation allowance: Year ended July 31, 2017 $ 2,334 $ 615 $ — $ 35 $ 2,984 Year ended July 31, 2016 $ 2,037 $ 929 $ (712 ) $ 80 $ 2,334 Year ended July 31, 2015 $ 3,538 $ 1,010 $ (2,420 ) (1) $ (91 ) $ 2,037 ________________________________________________ (1) The amounts primarily include deductions of valuation allowances associated with New Jersey net operating losses.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Cantel and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Certain prior year amounts have been reclassified to conform to the current year's presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, we evaluate the adequacy of our reserves and the estimates used in calculations of reserves as well as other judgmental financial statement items, including, but not limited to: collectability of accounts receivable, volume rebates and trade-in allowances, inventory values and obsolescence reserves, warranty reserves, contingent consideration, contingent guaranteed obligations, depreciation and amortization periods, deferred income taxes, goodwill and intangible assets, impairment of long-lived assets, unrecognized tax benefits for uncertain tax positions, reserves for legal exposure, stock-based compensation and expense accruals. Such estimates and assumptions are subjective in nature. We reflect such amounts based upon the most recent information available.
Subsequent Events	Subsequent Events We have evaluated subsequent events for disclosure through the date of issuance of the accompanying consolidated financial statements.
Revenue Recognition	Revenue Recognition Revenue on product sales is recognized as products are shipped to customers and title passes. The passing of title is determined based upon the FOB terms specified for each shipment. With respect to endoscopy and dialysis products, shipment terms are generally FOB origin for common carrier and when our distribution fleet is utilized (except for one large customer in dialysis and several endoscopy customers whereby all products are shipped FOB destination). With respect to water purification and filtration and healthcare disposable products, shipment terms may be either FOB origin or destination. Customer acceptance for the majority of our product sales occurs at the time of delivery. With respect to a portion of water purification and filtration and endoscopy product sales, equipment is sold as part of a system for which the equipment is functionally interdependent or the customer’s purchase order specifies “ship-complete” as a condition of delivery; revenue recognition on such sales is deferred until all equipment has been delivered, or post-delivery obligations such as installation have been substantially fulfilled such that the products are deemed functional by the end-user. All shipping and handling fees invoiced to customers, such as freight, are recorded as revenue (and related costs are included within cost of sales) at the time the sale is recognized. A portion of our endoscopy, water purification and filtration and dialysis sales are recognized as multiple element arrangements, whereby revenue is allocated to the equipment, installation and consumable components based upon vendor specific objective evidence, which includes comparable historical transactions of similar equipment, installation and consumables sold as stand-alone components. If vendor-specific objective evidence of selling price is not available, we allocate revenue to the elements of the bundled arrangement using the estimated selling price method in order to qualify the components as separate units of accounting. Revenue on the equipment and consumables components are recognized as the equipment or consumable is shipped to customers and title passes. Revenue on the installation component is recognized when the installation is complete. A portion of our healthcare disposables sales relating to the mail-in spore test kit is recorded as deferred revenue when initially sold. We recognize the revenue on these test kits using an estimate based on historical experience of the amount of time that elapses from the point of sale to when the kit is returned to us and we communicate to the customer the results of the required laboratory test. The related cost of the kits is recorded in inventory and recognized in cost of sales as the revenue is earned. Revenue on service sales is recognized when repairs are completed at the customer’s location or when repairs are completed at our facilities and the products are shipped to customers. With respect to certain service contracts in our Endoscopy and Water Purification and Filtration operating segments, service revenue is recognized on a straight-line basis over the contractual term of the arrangement. Our endoscopy products and services are sold directly to hospitals and other end-users in the United States and primarily to distributors internationally except for the United Kingdom, Italy, Netherlands, Singapore, China and Germany where we sell directly to hospitals and other end-users. Water purification and filtration products and services are sold directly to hospitals, dialysis clinics, pharmaceutical and biotechnology companies, laboratories, medical products and service companies and other end-users as well as through third-party distributors. The majority of our healthcare disposable products are sold to third party distributors, and with respect to some of our sterility assurance products, to hospitals, surgery centers, physician and dental offices, dental schools, medical research companies, laboratories and other end-users. The majority of our dialysis products are sold to dialysis clinics and hospitals. Sales to all of these customers follow our revenue recognition policies. None of our sales contain right-of-return provisions. Customer claims for credit or return due to damage, defect, shortage or other reason must be pre-approved by us before credit is issued or such product is accepted for return. No cash discounts for early payment are offered except with respect to a small portion of our product sales in each segment. We do not offer price protection, although advance pricing contracts or required notice periods prior to implementation of price increases exist for certain customers with respect to many of our products. With respect to certain of our dialysis, healthcare disposables, water purification and filtration and endoscopy customers, rebates are provided; such rebates, which consist primarily of volume rebates, are provided for as a reduction of sales at the time of revenue recognition and amounted to $6,291 , $5,944 , and $5,597 in fiscal 2017 , 2016 , and 2015 , respectively. Such allowances are determined based on estimated projections of sales volume for the entire rebate periods. If it becomes known that sales volume to customers will deviate from original projections, the rebate provisions originally established would be adjusted accordingly.
Translation of Foreign Currency Financial Statements	Translation of Foreign Currency Financial Statements Assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at year-end exchange rates; sales and expenses are translated using average exchange rates during the year. The cumulative effect of the translation of the accounts of the foreign subsidiaries is presented as a component of accumulated other comprehensive income or loss. Foreign exchange gains and losses related to the purchase of inventories denominated in foreign currencies are included in cost of sales and foreign exchange gains and losses related to the incurrence of operating costs denominated in foreign currencies and the conversion of foreign assets and liabilities into functional currencies are included in general and administrative expenses.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable consist of amounts due to us from normal business activities. Allowances for doubtful accounts are reserves for the estimated loss from the inability of customers to make required payments. We use historical experience as well as current market information in determining the estimate. While actual losses have historically been within management’s expectations and provisions established, if the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Alternatively, if certain customers paid their delinquent receivables, reductions in allowances may be required.
Inventories	Inventories Inventories consist of raw materials, work-in-process and finished products which are sold in the ordinary course of our business and are stated at the lower of cost (first-in, first-out) or market. In assessing the value of inventories, we must make estimates and judgments regarding reserves required for product obsolescence, aging of inventories and other issues potentially affecting the saleable condition of products. In performing such evaluations, we use historical experience as well as current market information. With few exceptions, the saleable value of our inventories has historically been within management’s expectation and provisions established, however, rapid changes in the market due to competition, technology and various other factors could impact the value of our inventories, resulting in the need for additional reserves.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Additions and improvements are capitalized, while maintenance and repair costs are expensed. When assets are retired or otherwise disposed, the cost and related accumulated depreciation or amortization is removed from the respective accounts and any resulting gain or loss is included in income. Depreciation and amortization is provided on the straight-line method over the estimated useful lives of the assets which generally range from 2 - 15 years for furniture and equipment, 5 - 32 years for buildings and improvements and the shorter of the life of the asset or the life of the lease for leasehold improvements.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Certain of our identifiable intangible assets, including customer relationships, technology, brand names, non-compete agreements and patents, are amortized using the straight-line method over their estimated useful lives which range from 3 to 20 years. Additionally, we have recorded goodwill and trademarks and trade names, all of which have indefinite useful lives and are therefore not amortized. All of our intangible assets and goodwill are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, and goodwill and intangible assets with indefinite lives are reviewed for impairment at least annually . Our management is responsible for determining if impairment exists and considers a number of factors, including third-party valuations, when making these determinations. We first assess qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount before proceeding to step one of the two-step quantitative goodwill impairment test, if necessary. Such qualitative factors that are assessed include evaluating a segment’s financial performance, industry and market conditions, macroeconomic conditions and specific issues that can directly affect the segment such as changes in business strategies, competition, supplier relationships, operating costs, regulatory matters, litigation and the composition of the segment’s assets due to acquisitions or other events. At July 31, 2017 , because we determined through qualitative factors that the fair values of our Endoscopy, Water Purification and Filtration and Healthcare Disposables segments were unlikely to be less than the carrying value, we did not proceed to step one of the two-step quantitative goodwill impairment test for those three segments. We performed step one of the two-step quantitative goodwill impairment test for Dialysis due to the continuing shift by our customers from reusable to single-use dialyzers, which is having an adverse impact on our business and is expected to continue. In performing a detailed quantitative review for goodwill impairment, management uses a two-step process that begins with an estimation of the fair value of the related reporting units by using weighted fair value results of the discounted cash flow methodology, as well as the market multiple and comparable transaction methodologies, where applicable. The first step is a review for potential impairment, and the second step measures the amount of impairment, if any. We perform our annual impairment review for indefinite lived intangibles by first assessing qualitative factors, such as those described above, to determine whether it is more likely than not that the fair value of such assets is less than the carrying values, and if necessary, we perform a quantitative analysis comparing the current fair value of our indefinite lived intangibles assets to their carrying values. At July 31, 2017 , because we determined through qualitative factors that the fair values of all of our indefinite lived intangible assets were unlikely to be less than the carrying value, we did not perform a quantitative analysis for those assets. With respect to amortizable intangible assets when impairment indicators are present, management would determine whether expected future non-discounted cash flows would be sufficient to recover the carrying value of the assets; if not, the carrying value of the assets would be adjusted to their fair value. Management concluded that none of our intangible assets or goodwill was impaired as of July 31, 2017 .
Long-Lived Assets	Long-Lived Assets We evaluate the carrying value of long-lived assets including property, equipment and other assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. An assessment is made to determine if the sum of the expected future non-discounted cash flows from the use of the assets and eventual disposition is less than the carrying value. If the sum of the expected non-discounted cash flows is less than the carrying value, an impairment loss is recognized based on fair value. With the exception of the impairment on an acquired license, our historical assessments of our long-lived assets have not differed significantly from the actual amounts realized. See Note 8, "Intangibles and Goodwill." However, the determination of fair value requires us to make certain assumptions and estimates and is highly subjective. On July 31, 2017 , management concluded that no other events or changes in circumstances have occurred that would indicate that the carrying amount of our long-lived assets may not be recoverable.
Other Assets	Other Assets Debt issuance costs associated with our credit facilities are amortized to interest expense over the life of the credit facilities.
Warranties	Warranties We provide for estimated costs that may be incurred to remedy deficiencies of quality or performance of our products at the time of revenue recognition. Most of our products have a one year warranty, although certain endoscopy and water purification and filtration products that require installation may carry a warranty period of up to 24 months . Additionally, many of our consumables, accessories, parts and service have a 90 day warranty. We record provisions for product warranties as a component of cost of sales based upon an estimate of the amounts necessary to settle existing and future claims on products sold. The historical relationship of warranty costs to products sold is the primary basis for the estimate. A significant increase in third party service repair rates, the cost and availability of parts or the frequency of claims could have a material impact on our results for the period or periods in which such claims or additional costs materialize. Management reviews its warranty exposure periodically and believes that the warranty reserves are adequate; however, actual claims incurred could differ from original estimates, requiring adjustments to the reserves.
Stock-Based Compensation	Stock-Based Compensation Stock compensation expense is recognized for any option or stock award grant based upon the fair value of the award. Our stock options and time-based stock awards are subject to graded vesting in which portions of the award vest ratably over the vesting period. We recognize compensation expense for awards subject to graded vesting using the straight-line basis over the vesting period. In October 2016, we granted for the first time to certain employees equity awards with performance conditions and equity awards with market conditions. We recognize compensation expense for the awards with performance conditions using the accelerated attribution method over the requisite service period for each separately vesting portion of the award when it is probable that the performance condition will be achieved. We record expense for the awards with market conditions ratably over the vesting period regardless of whether the market condition is satisfied. As a result of the adoption of ASU 2016-09 on August 1, 2016, we have elected to account for forfeitures as they occur, rather than estimate forfeitures over the course of the vesting period.
Advertising Costs	Advertising Costs Our policy is to expense advertising costs as they are incurred.
Income Taxes	Income Taxes Our provision for income taxes is based on our current period income, changes in deferred income tax assets and liabilities, statutory income tax rates, changes in uncertain tax benefits and the deductibility of expenses or availability of tax credits in various taxing jurisdictions. Tax laws are complex, subject to different interpretations by the taxpayer and the respective governmental taxing authorities and are subject to future modification, expiration or repeal by government legislative bodies. We use significant judgment on a quarterly basis in determining our annual effective income tax rate and evaluating our tax positions. We regularly review our deferred tax assets for recoverability and establish a valuation allowance, if necessary, based on historical taxable income, projected future taxable income, and the expected timing of the reversals of existing temporary differences. Although realization is not assured, management believes it is more likely than not that the recorded deferred tax assets, as adjusted for valuation allowances, will be realized. Additionally, deferred tax liabilities are regularly reviewed to confirm that such amounts are appropriately stated. A review of our deferred tax items considers known future changes in various income tax rates, principally in the United States. If income tax rates were to change in the future, particularly in the United States and to a lesser extent Canada, the U.K. and Italy, our items of deferred tax could be materially affected. All of such evaluations require significant management judgments. We record liabilities for an unrecognized tax benefit when a tax benefit for an uncertain tax position is taken or expected to be taken on a tax return, but is not recognized in our consolidated financial statements because it does not meet the more-likely-than-not recognition threshold that the uncertain tax position would be sustained upon examination by the applicable taxing authority. Any adjustments upon resolution of income tax uncertainties are recognized in our results of operations. Unrecognized tax benefits are analyzed periodically and adjustments are made as events occur to warrant adjustment to the related liability. Historically, we have not had significant unrecognized tax benefits.
Recently Issued Accounting Standards	Newly Adopted Accounting Standards In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-09, “ Improvements to Employee Share-Based Payment Accounting ” (“ASU 2016-09”), which simplifies the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures and statutory tax withholding requirements. The new guidance also requires that all tax-related cash flows resulting from share-based payments to be reported as operating activities in the statement of cash flows. We early adopted ASU 2016-09 on August 1, 2016, on a prospective basis. As a result, we no longer record excess tax benefits as an adjustment to additional paid-in capital, we record such excess tax benefits as a reduction of income tax expense, which amounted to $2,241 for the year ended July 31, 2017. See Note 11, "Income Taxes" and Note 15, "Stock-based Compensation." In addition, we elected to record excess tax benefits as an operating cash flow prospectively and not adjust the prior year period. As such, the current period excess tax benefits were reflected as an operating cash flow rather than a financing cash flow on our consolidated statement of cash flows for the year ended July 31, 2017. Furthermore, we have elected to account for forfeitures as they occur, rather than estimate expected forfeitures over the course of a vesting period since forfeitures have been insignificant historically. Recently Issued Accounting Standards In May 2017, the FASB issued ASU 2017-09, " Scope of Modification Accounting " ("ASU 2017-09") to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-12 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. We are currently in the process of evaluating the impact of ASU 2017-09 on our financial position and result of operations. In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other” (“ASU 2017-04”) to simplify the test for goodwill impairment. The revised guidance eliminates the existing Step 2 of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. Under the revised guidance, an entity would recognize an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value; however, the loss recognized would not exceed the total amount of goodwill allocated to the reporting unit. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-04 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020) and early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a significant impact on our financial position and result of operations. In January 2017, the FASB issued ASU 2017-01, “ Business Combinations (Topic 805)” (“ASU 2017-01”) to clarify the definition of a business. The revised guidance creates a more robust framework to use in determining whether a set of assets and activities is a business. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. We are currently in the process of evaluating the impact of ASU 2017-01 on our financial position and result of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows” (“ASU 2016-15”). This new guidance will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019). ASU 2016-15 will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. We are currently in the process of evaluating the impact of ASU 2016-15 on our financial position and result of operations. In February 2016, FASB issued ASU 2016-02, “ Leases (Topic 842) ” (“ASU 2016-02”). The new guidance requires the recording of assets and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. The new guidance is expected to provide transparency of information and comparability among organizations. ASU 2016-02 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. We are currently in the process of evaluating the impact of ASU 2016-02 on our financial position and results of operations. In September 2015, the FASB issued ASU 2015-16, “ Simplifying the Accounting for Measurement-Period Adjustments (Topic 805)” (“ASU 2015-16”). The new guidance requires an acquirer in a business combination to recognize a measurement-period adjustment during the period in which it determines the amount, and eliminates the requirement for an acquirer to account for measurement-period adjustments retrospectively. The acquirer must also disclose the amounts and reasons for adjustments to the provisional amounts. ASU 2015-16 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we will adopt ASU 2015-06 in our first quarter of fiscal 2018. The adoption of ASU 2015-06 is not expected to have a material impact upon on our financial position and results of operations. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330) Simplifying the Measurement of Inventory,” (“ASU 2015-11”). The new guidance requires companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016 (our fiscal year 2018), including interim periods within that reporting period. Accordingly, we will adopt ASU 2015-11 in our first quarter of fiscal 2018. The adoption of ASU 2015-11 is not expected to have a material impact upon on our financial position and results of operations. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”), which will supersede the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition” ("ASC 605"). ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606),” which defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2016-12”), which provided narrow scope improvements and practical expedients relating to ASU 2014-09. In preparation for our adoption of ASU 2014-09 and ASU 2016-12 on August 1, 2018, we are obtaining representative samples of contracts and other forms of agreements with our customers in the United States and international locations and plan to evaluate the provisions contained therein in light of the five-step model specified by the new guidance. We are also evaluating the impact of the new standard on certain common practices currently employed by us and by other health care manufacturers and service providers, such as multiple-element arrangements, deferred revenues, warranties, rebates and other pricing allowances. We anticipate adopting the standard using the modified retrospective method. There may be differences in timing of revenue recognition under the new standard compared to recognition under ASC 605.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jul. 31, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	2017 2016 Purchase Price Allocation CR Kennedy Vantage (1) Accutron (1) NAMSA (1) MI Purchase Price: Cash paid $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 Debt acquired — — — — — Total $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 Allocation: Property and equipment — 433 1,676 437 6,464 Amortizable intangible assets: Customer relationships 4,200 992 12,800 5,820 24,430 Technology — — 10,000 1,320 10,930 Brand names — — 2,000 — 2,030 Goodwill 5,894 2,299 21,989 3,687 40,006 Deferred income taxes — — 112 — (8,683 ) Other working capital 1,905 320 4,472 2,160 4,420 Total $ 11,999 $ 4,044 $ 53,049 $ 13,424 $ 79,597 _______________________________________________ (1) The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Summary of inventories	A summary of inventories, net, is as follows: July 31, 2017 2016 Raw materials and parts $ 45,831 $ 45,867 Work-in-process 13,484 13,178 Finished goods 48,262 37,831 Less: reserve for excess and obsolete inventory (8,853 ) (5,390 ) Total $ 98,724 $ 91,486

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of property and equipment	A summary of property and equipment, net, is as follows: July 31, 2017 2016 Land, buildings and improvements $ 46,921 $ 44,387 Furniture and equipment 119,682 95,033 Leasehold improvements 7,858 6,048 Less: accumulated depreciation (86,123 ) (70,864 ) Total $ 88,338 $ 74,604

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jul. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of fair values of financial instruments measured on a recurring basis	The fair values of the Company’s financial instruments measured on a recurring basis were categorized as follows: July 31, 2017 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 102 $ — $ — $ 102 Total assets 102 — — 102 Liabilities: Accrued expenses: Assumed contingent obligation — — 12 12 Contingent guaranteed obligation — — — — Total accrued expenses — — 12 12 Long-term debt (1) — 126,000 — 126,000 Other long-term liabilities: Assumed contingent obligation — — 1,126 1,126 Contingent guaranteed obligation — — — — Total other long-term liabilities: — — 1,126 1,126 Total liabilities $ — $ 126,000 $ 1,138 $ 127,138 ________________________________________________ (1) Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active. July 31, 2016 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 740 $ — $ — $ 740 Total assets $ 740 $ — $ — $ 740 Liabilities: Accrued expenses: Assumed contingent obligation — — 12 12 Contingent guaranteed obligation — — 366 366 Total accrued expenses — — 378 378 Long-term debt (1) — 116,000 — 116,000 Other long-term liabilities: Contingent consideration — — — — Assumed contingent obligation — — 1,126 1,126 Contingent guaranteed obligation — — 75 75 Total other long-term liabilities: — — 1,201 1,201 Total liabilities $ — $ 116,000 $ 1,579 $ 117,579 ________________________________________________ (1) Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active.
Reconciliation of liabilities measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3)	A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) for fiscal 2017 , 2016 and 2015 is as follows: Jet Prep Contingent Consideration Jet Prep Assumed Contingent Obligation Cantel Medical (U.K.) Contingent Guaranteed Obligation Total Balance, July 31, 2014 $ 2,722 $ 1,752 $ 1,395 $ 5,869 Total net unrealized gains included in general and administrative expense in earnings (1,971 ) (614 ) — (2,585 ) Net purchases, issuances, sales and settlements — — (507 ) (507 ) Balance, July 31, 2015 751 1,138 888 2,777 Total net unrealized (gains) losses included in general and administrative expense in earnings (751 ) — 64 (687 ) Net purchases, issuances, sales and settlements — — (511 ) (511 ) Balance, July 31, 2016 — 1,138 441 1,579 Total net unrealized gains included in general and administrative expense in earnings — — (265 ) (265 ) Net purchases, issuances, sales and settlements — — (176 ) (176 ) Balance, July 31, 2017 $ — $ 1,138 $ — $ 1,138

Intangibles and Goodwill (Table

Intangibles and Goodwill (Tables)	12 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	The Company’s intangible assets consist of the following: July 31, 2017 July 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships $ 119,576 $ (34,773 ) $ 84,803 $ 100,649 $ (24,689 ) $ 75,960 Technology 42,794 (18,990 ) 23,804 32,767 (11,813 ) 20,954 Brand names 8,188 (3,225 ) 4,963 6,194 (2,394 ) 3,800 Non-compete agreements 3,092 (1,428 ) 1,664 3,092 (1,193 ) 1,899 Patents and other registrations 2,783 (1,053 ) 1,730 2,508 (913 ) 1,595 176,433 (59,469 ) 116,964 145,210 (41,002 ) 104,208 Trademarks and tradenames 7,548 — 7,548 7,511 — 7,511 Total intangible assets $ 183,981 $ (59,469 ) $ 124,512 $ 152,721 $ (41,002 ) $ 111,719
Schedule of changes in goodwill	Goodwill changed during fiscal 2017 and 2016 as follows: Endoscopy Water Purification and Filtration Healthcare Disposables Dialysis Total Goodwill Balance, July 31, 2015 $ 87,007 $ 58,872 $ 87,939 $ 8,133 $ 241,951 Acquisitions 40,047 — 4,351 — 44,398 Foreign currency translation (6,039 ) 8 — — (6,031 ) Balance, July 31, 2016 121,015 58,880 92,290 8,133 280,318 Acquisitions 8,193 — 21,989 — 30,182 Foreign currency translation 737 208 — — 945 Balance, July 31, 2017 $ 129,945 $ 59,088 $ 114,279 $ 8,133 $ 311,445

Warranties (Tables)

Warranties (Tables)	12 Months Ended
	Jul. 31, 2017
Product Warranties Disclosures [Abstract]
Summary of activity in warranty reserves	A summary of activity in the warranty reserves follows: Year Ended July 31, 2017 2016 Beginning balance $ 2,575 $ 1,740 Acquisitions 179 28 Provisions 4,880 4,554 Settlements (5,306 ) (3,622 ) Foreign currency translation — (125 ) Ending balance $ 2,328 $ 2,575

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of provision for income taxes	The provision for income taxes consists of the following: Year Ended July 31, 2017 2016 2015 Current Deferred Current Deferred Current Deferred United States: Federal $ 28,900 $ 2,020 $ 29,392 $ (216 ) $ 24,602 $ (425 ) State 4,352 261 4,433 (153 ) 3,920 (218 ) International 1,545 (2,223 ) 1,863 (1,341 ) 1,165 (806 ) Total $ 34,797 $ 58 $ 35,688 $ (1,710 ) $ 29,687 $ (1,449 )
Schedule of geographic components of income before income taxes	The geographic components of income before income taxes are as follows: Year Ended July 31, 2017 2016 2015 United States $ 108,329 $ 92,744 $ 73,645 International (2,096 ) 1,187 2,546 Total $ 106,233 $ 93,931 $ 76,191
Schedule of reconciliation of differences in effective tax rate from the United States statutory tax rate	The consolidated effective income tax rate differed from the U.S. statutory tax rate of 35.0% in fiscal 2017 , 2016 and 2015 due to the following: Year Ended July 31, 2017 2016 2015 Expected statutory tax 35.0 % 35.0 % 35.0 % Differential attributable to: Foreign operations — % 0.6 % 1.2 % State and local taxes 3.9 % 3.2 % 3.4 % Domestic production deduction (2.7 )% (2.3 )% (2.4 )% Acquisition related items, net 0.1 % — % (1.6 )% Loss on sale of business — % — % 1.1 % R&E tax credit (1.4 )% (1.1 )% (0.5 )% Change in foreign tax rates — % (0.4 )% — % Excess tax benefits (2.2 )% — % — % Other 0.1 % 1.2 % 0.9 % Consolidated effective tax rate 32.8 % 36.2 % 37.1 %
Schedule of deferred income tax assets and liabilities	Deferred income tax assets and liabilities are comprised of the following: July 31, 2017 2016 Deferred tax assets: Accrued expenses $ 6,308 $ 5,140 Inventories 4,655 2,990 Accounts receivable 729 793 Other long-term liabilities 180 252 Stock-based compensation 3,402 3,665 Capital investment 545 546 Foreign NOLs 6,490 5,154 Subtotal 22,309 18,540 Valuation allowance (2,984 ) (2,334 ) 19,325 16,206 Deferred tax liabilities: Property and equipment (9,957 ) (8,089 ) Intangible assets (20,107 ) (19,818 ) Goodwill (13,975 ) (11,878 ) (44,039 ) (39,785 ) Net deferred tax liabilities - noncurrent $ (24,714 ) $ (23,579 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate annual required payments over the next five years and thereafter under contractual obligations that have long-term components	As of July 31, 2017, future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) for the periods set forth below were as follows: Fiscal year ending: Total 2018 $ 6,522 2019 5,278 2020 3,779 2021 2,719 2022 1,231 Thereafter 2,454 Total $ 21,983

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Jul. 31, 2017
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Loss	The components and changes in accumulated other comprehensive loss for fiscal 2017 , 2016 and 2015 were as follows: Foreign Currency Translation Adjustments Balance, July 31, 2014 $ 9,552 Other comprehensive loss before reclassification adjustments (7,064 ) Reclassification adjustment to loss on sale of business for foreign currency translation gain included in net income during the year (1,264 ) Balance, July 31, 2015 1,224 Other comprehensive loss (13,019 ) Balance, July 31, 2016 (11,795 ) Other comprehensive income 1,895 Balance, July 31, 2017 $ (9,900 )

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	12 Months Ended
	Jul. 31, 2017
Earnings Per Share [Abstract]
Schedule of computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities)	The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities): Year Ended July 31, 2017 2016 2015 Numerator for basic and diluted earnings per share: Net income $ 71,378 $ 59,953 $ 47,953 Less income allocated to participating securities (431 ) (488 ) (433 ) Net income available to common shareholders $ 70,947 $ 59,465 $ 47,520 Denominator for basic and diluted earnings per share, as adjusted for participating securities: Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock 41,468,487 41,344,013 41,139,467 Dilutive effect of stock options using the treasury stock method and the average market price for the year 74,278 46,181 63,133 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,542,765 41,390,194 41,202,600 Earnings per share attributable to common stock: Basic earnings per share $ 1.71 $ 1.44 $ 1.16 Diluted earnings per share $ 1.71 $ 1.44 $ 1.15 Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive — — —
Schedule of reconciliation of weighted average number of shares and common stock equivalents attributable to common stock to the Company's total weighted average number of shares and common stock equivalents including participating securities	A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to the Company’s total weighted average number of shares and common stock equivalents, including participating securities, is set forth in the following table: Year Ended July 31, 2017 2016 2015 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,542,765 41,390,194 41,202,600 Participating securities 254,727 340,363 378,706 Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities 41,797,492 41,730,557 41,581,306

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income	The following table shows the income statement components of stock-based compensation expense recognized in the consolidated statements of income: Year Ended July 31, 2017 2016 2015 Cost of sales $ 371 $ 438 $ 270 Operating expenses: Selling 1,582 929 608 General and administrative 6,774 6,881 4,897 Research and development 117 113 92 Total operating expenses 8,473 7,923 5,597 Stock-based compensation before income taxes $ 8,844 $ 8,361 $ 5,867
Summary of nonvested stock award activity	A summary of nonvested stock award activity for the year ended July 31, 2017 follows: Number of Time-based Shares Number of Performance-based Shares Number of Market-based Shares Number of Total Shares Weighted Average Fair Value July 31, 2014 525,842 — — 525,842 $ 22.25 Granted 144,278 — — 144,278 $ 39.77 Vested (1) (313,797 ) — — (313,797 ) $ 18.62 Forfeited (12,804 ) — — (12,804 ) $ 26.20 July 31, 2015 343,519 — — 343,519 $ 32.77 Granted 175,700 — — 175,700 $ 55.40 Vested (1) (183,045 ) — — (183,045 ) $ 30.06 Forfeited (4,807 ) — — (4,807 ) $ 45.06 July 31, 2016 331,367 — — 331,367 $ 46.09 Granted 86,305 16,960 9,800 113,065 $ 81.77 Vested (1) (214,932 ) (725 ) (555 ) (216,212 ) $ 43.62 Forfeited (5,922 ) — — (5,922 ) $ 59.40 July 31, 2017 196,818 16,235 9,245 222,298 $ 66.28
Weighted-average assumptions used to estimate fair value of stock options granted using the Black-Scholes option valuation model	The fair value of each option grant in the prior years was estimated on the date of grant using the Black-Scholes option valuation model with the following assumptions: Year Ended Year Ended July 31, 2016 July 31, 2015 Dividend yield 0.22 % 0.25 % Expected volatility (1) 55.90 % 33.90 % Risk-free interest rate (2) 1.41 % 1.55 % Expected lives (in years) (3) 5.00 5.00 ________________________________________________ (1) Volatility was based on historical closing prices of our common stock. (2) The U.S. Treasury rate based on the expected life at the date of grant. (3) Based on historical exercise behavior. We determine the fair value of each stock award with market conditions using the Monte Carlo simulation on the date of grant using the following assumptions: Year Ended July 31, 2017 Volatility of common stock 27.75 % Average volatility of peer companies 32.98 % Average correlation coefficient of peer companies 35.35 % Risk-free interest rate 0.96 %
Summary of stock option activity	A summary of stock option activity for the year ended July 31, 2017 follows: Number of shares Weighted Average Exercise Price Weighted Average Contractual Life Remaining (Years) Aggregate Intrinsic Value Outstanding at July 31, 2016 122,500 $ 29.36 Granted — — Exercised — — Outstanding at July 31, 2017 122,500 $ 29.36 1.27 $ 5,493 Exercisable at July 31, 2017 104,167 $ 26.28 1.02 $ 4,992

Information as to Reportable 39

Information as to Reportable Segments and Foreign and Domestic Operations (Tables)	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Information as to operating segments	Information as to reportable segments is summarized below: Year Ended July 31, 2017 2016 2015 Net sales: Endoscopy $ 398,773 $ 341,752 $ 248,654 Water Purification and Filtration 196,446 177,669 173,834 Healthcare Disposables 144,457 112,584 106,920 Dialysis 30,481 32,750 31,240 Other — — 4,356 Total $ 770,157 $ 664,755 $ 565,004 Year Ended July 31, 2017 2016 2015 Operating income: Endoscopy $ 73,440 $ 61,021 $ 40,863 Water Purification and Filtration 33,159 30,620 30,606 Healthcare Disposables 28,000 24,486 19,904 Dialysis 8,154 7,907 6,749 Other — — 1,118 142,753 124,034 99,240 General corporate expenses 32,343 26,783 18,479 Income from operations 110,410 97,251 80,761 Interest expense, net 4,303 3,320 2,364 Other income (126 ) — — Loss on sale of business — — 2,206 Income before income taxes $ 106,233 $ 93,931 $ 76,191 Year Ended July, 31 2017 2016 2015 Identifiable assets: Endoscopy $ 368,820 $ 347,107 $ 238,799 Water Purification and Filtration 147,477 137,731 138,069 Healthcare Disposables 208,328 157,918 145,391 Dialysis 17,211 20,147 26,452 General corporate, including cash and cash equivalents 44,537 31,629 35,320 Total $ 786,373 $ 694,532 $ 584,031 Year Ended July, 31 2017 2016 2015 Capital expenditures: Endoscopy $ 13,816 $ 11,299 $ 7,042 Water Purification and Filtration 3,689 3,376 2,984 Healthcare Disposables 2,492 2,606 1,587 Dialysis 1,296 667 894 Other — — 19 General corporate 5,772 941 234 Total $ 27,065 18,889 12,760 Year Ended July, 31 2017 2016 2015 Depreciation and amortization: Endoscopy $ 18,245 $ 14,333 $ 10,729 Water Purification and Filtration 5,706 5,441 5,257 Healthcare Disposables 8,556 4,361 6,354 Dialysis 427 681 1,382 Other — — 78 General corporate 518 268 157 Total $ 33,452 $ 25,084 $ 23,957
Information as to geographic areas	Information as to geographic areas (including net sales which represent the geographic area from which the Company derives its net sales from external customers) is summarized below: Year Ended July, 31 2017 2016 2015 Net sales: United States $ 599,657 $ 515,055 $ 447,848 Europe/Africa/Middle East 95,753 88,355 62,193 Asia/Pacific 40,964 33,374 28,529 Canada 26,648 20,975 19,306 Latin America/South America 7,135 6,996 7,128 Total $ 770,157 $ 664,755 $ 565,004 July 31, 2017 2016 2015 Total long-lived assets: United States $ 74,401 $ 62,820 $ 57,080 Europe/Africa/Middle East 16,209 14,863 9,122 Asia/Pacific 1,381 1,607 1,081 Canada 1,054 463 600 Total 93,045 79,753 67,883 Goodwill and intangible assets, net 435,957 392,037 327,787 Total $ 529,002 $ 471,790 $ 395,670

Quarterly Results of Operatio40

Quarterly Results of Operations (Tables)	12 Months Ended
	Jul. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Summary of quarterly results of operations	The following is a summary of the quarterly results of operations for the years ended July 31, 2017 and 2016 : 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 187,725 $ 184,817 $ 192,113 $ 205,502 Cost of sales 98,218 96,340 100,665 107,774 Gross profit 89,507 88,477 91,448 97,728 Gross profit percentage 47.7 % 47.9 % 47.6 % 47.6 % Net income $ 18,800 $ 18,070 $ 17,511 $ 16,997 Earnings per common share: Basic $ 0.45 $ 0.43 $ 0.42 $ 0.41 Diluted $ 0.45 $ 0.43 $ 0.42 $ 0.41 2016 First Quarter Second Quarter Third Quarter Fourth Quarter Net sales $ 153,779 $ 158,271 $ 173,703 $ 179,002 Cost of sales 82,581 85,934 93,382 93,672 Gross profit 71,198 72,337 80,321 85,330 Gross profit percentage 46.3 % 45.7 % 46.2 % 47.7 % Net income $ 14,254 $ 15,389 $ 14,019 $ 16,291 Earnings per common share: Basic $ 0.34 $ 0.37 $ 0.34 $ 0.39 Diluted $ 0.34 $ 0.37 $ 0.34 $ 0.39

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Revenue (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)customer	Jul. 31, 2016USD ($)	Jul. 31, 2015USD ($)
Revenue recognition - reductions
Number of customers with products shipped FOB destination | customer	1
Volume rebates | $	$ 6,291	$ 5,944	$ 5,597

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 15,045	$ 11,989	$ 10,692
Furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	32 years

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Intangible Assets (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets impairment	$ 0
Goodwill impairment	$ 0
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Other Assets (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Credit Agreement
Debt Instrument [Line Items]
Net debt issuance costs	$ 580	$ 946

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Warranties (Details)	12 Months Ended
	Jul. 31, 2017
Most products
Product Warranties Disclosures [Abstract]
Warranty period	1 year
Endoscopy, Water Purification and Filtration products
Product Warranties Disclosures [Abstract]
Warranty period	24 months
Consumables, accessories and parts
Product Warranties Disclosures [Abstract]
Warranty period	90 days

Summary of Significant Accoun46

Summary of Significant Accounting Policies - Other (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Advertising Costs
Advertising costs charged to expense	$ 3,694	$ 3,349	$ 3,333
Stock-Based Compensation
Share-based compensation, excess tax benefit, amount	$ 2,241	$ 1,179

Acquisitions - CR Kennedy & Com

Acquisitions - CR Kennedy & Company (Details) - USD ($) $ in Thousands	Apr. 01, 2017	Jul. 31, 2017
CR Kennedy & Company
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 11,999	$ 11,999

Acquisitions Acquisitions - Van

Acquisitions Acquisitions - Vantage Endoscopy Inc. (Details) - USD ($) $ in Thousands	Sep. 26, 2016	Jul. 31, 2017
Vantage Endoscopy Inc
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 4,044	$ 4,044	[1]
[1]	The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Acquisitions - Accutron (Detail

Acquisitions - Accutron (Details) - USD ($) $ in Thousands		Aug. 01, 2016	Jul. 31, 2017
Accutron, Inc.
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	[1]	$ 53,049	$ 53,049
[1]	The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Acquisitions - NAMSA (Details)

Acquisitions - NAMSA (Details) - USD ($) $ in Thousands		Mar. 01, 2016	Jul. 31, 2016
North American Science Associates Inc
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	[1]	$ 13,424	$ 13,424
[1]	The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Acquisitions - MI (Details)

Acquisitions - MI (Details) - USD ($) $ in Thousands	Sep. 14, 2015	Jul. 31, 2016
Medical Innovations Group Holdings Limited
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 79,597	$ 79,597

Acquisitions - BHT (Details)

Acquisitions - BHT (Details) - USD ($) $ in Thousands		Aug. 23, 2017	Apr. 01, 2017	Sep. 26, 2016	Aug. 01, 2016	Mar. 01, 2016	Sep. 14, 2015	Jul. 31, 2017		Jul. 31, 2016	Jul. 31, 2015
Business Acquisition [Line Items]
Goodwill								$ 311,445		$ 280,318	$ 241,951
BHT | Subsequent Events
Business Acquisition [Line Items]
Total consideration, excluding acquisition costs		$ 61,236
CR Kennedy
Business Acquisition [Line Items]
Cash paid								11,999
Debt acquired								0
Total			$ 11,999					11,999
Property and equipment								0
Goodwill								5,894
Deferred income taxes								0
Other working capital								1,905
Total								11,999
CR Kennedy | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:								4,200
CR Kennedy | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:								0
CR Kennedy | Brand names
Business Acquisition [Line Items]
Amortizable intangible assets:								0
Vantage1
Business Acquisition [Line Items]
Cash paid	[1]							4,044
Debt acquired	[1]							0
Total				$ 4,044				4,044	[1]
Property and equipment	[1]							433
Goodwill	[1]							2,299
Deferred income taxes	[1]							0
Other working capital	[1]							320
Total	[1]							4,044
Vantage(1) | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							992
Vantage(1) | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							0
Vantage(1) | Brand names
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							0
Accutron
Business Acquisition [Line Items]
Cash paid	[1]							53,049
Debt acquired	[1]							0
Total	[1]				$ 53,049			53,049
Property and equipment	[1]							1,676
Goodwill	[1]							21,989
Deferred income taxes	[1]							112
Other working capital	[1]							4,472
Total	[1]							53,049
Accutron | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							12,800
Accutron | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							10,000
Accutron | Brand names
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]							$ 2,000
NAMSA
Business Acquisition [Line Items]
Cash paid										13,424
Debt acquired	[1]									0
Total	[1]					$ 13,424				13,424
Property and equipment	[1]									437
Goodwill	[1]									3,687
Deferred income taxes	[1]									0
Other working capital	[1]									2,160
Total	[1]									13,424
NAMSA | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]									5,820
NAMSA | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]									1,320
NAMSA | Brand names
Business Acquisition [Line Items]
Amortizable intangible assets:	[1]									0
MI
Business Acquisition [Line Items]
Cash paid										79,597
Debt acquired										0
Total							$ 79,597			79,597
Property and equipment										6,464
Goodwill										40,006
Deferred income taxes										(8,683)
Other working capital										4,420
Total										79,597
MI | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:										24,430
MI | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:										10,930
MI | Brand names
Business Acquisition [Line Items]
Amortizable intangible assets:										$ 2,030
[1]	The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Inventory Disclosure [Abstract]
Raw materials and parts	$ 45,831	$ 45,867
Work-in-process	13,484	13,178
Finished goods	48,262	37,831
Less: reserve for excess and obsolete inventory	(8,853)	(5,390)
Total	$ 98,724	$ 91,486

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (86,123)	$ (70,864)
Property and equipment, net	88,338	74,604
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	46,921	44,387
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	119,682	95,033
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,858	$ 6,048

Derivatives (Details)

Derivatives (Details) - Foreign currency forward contracts - Designated as hedging instrument - Fair value hedge instruments $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)contract
Derivatives
Term of contracts	1 month
Number of contracts | contract	9
Aggregate value of contracts | $	$ 24,762
Term of renewed contracts	1 month

Fair Value Measurements - Recur

Fair Value Measurements - Recurring Basis (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Jet Prep Ltd.
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
Assumed contingent obligation	$ 1,138
Level 3 | Recurring basis | Cantel Medical (UK) - PuriCore International Limited
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
Fair value of contingent liability	0	$ 441
Level 3 | Recurring basis | Jet Prep Ltd.
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
Assumed contingent obligation	$ 1,138

Fair Value Measurements - Hiera

Fair Value Measurements - Hierarchy Levels (Details) - Recurring basis - USD ($) $ in Thousands		Jul. 31, 2017	Jul. 31, 2016
Assets:
Total assets		$ 102	$ 740
Liabilities:
Total liabilities		127,138	117,579
Accrued expenses:
Liabilities:
Assumed contingent obligation		12	12
Contingent guaranteed obligation		0	366
Total accrued expenses		12	378
Long-term debt	[1]	126,000	116,000
Other long-term liabilities:
Liabilities:
Contingent consideration			0
Assumed contingent obligation		1,126	1,126
Contingent guaranteed obligation		0	75
Total other long-term liabilities:		1,126	1,201
Money markets | Cash and cash equivalents:
Assets:
Money markets		102	740
Level 1
Assets:
Total assets		102	740
Liabilities:
Total liabilities		0	0
Level 1 | Accrued expenses:
Liabilities:
Assumed contingent obligation		0	0
Contingent guaranteed obligation		0	0
Total accrued expenses		0	0
Long-term debt	[1]	0	0
Level 1 | Other long-term liabilities:
Liabilities:
Contingent consideration			0
Assumed contingent obligation		0	0
Contingent guaranteed obligation		0	0
Total other long-term liabilities:		0	0
Level 1 | Money markets | Cash and cash equivalents:
Assets:
Money markets		102	740
Level 2
Assets:
Total assets		0	0
Liabilities:
Total liabilities		126,000	116,000
Level 2 | Accrued expenses:
Liabilities:
Assumed contingent obligation		0	0
Contingent guaranteed obligation		0	0
Total accrued expenses		0	0
Long-term debt		126,000	116,000
Level 2 | Other long-term liabilities:
Liabilities:
Contingent consideration			0
Assumed contingent obligation		0	0
Contingent guaranteed obligation		0	0
Total other long-term liabilities:		0	0
Level 2 | Money markets | Cash and cash equivalents:
Assets:
Money markets		0	0
Level 3
Assets:
Total assets		0	0
Liabilities:
Total liabilities		1,138	1,579
Level 3 | Accrued expenses:
Liabilities:
Assumed contingent obligation		12	12
Contingent guaranteed obligation		0	366
Total accrued expenses		12	378
Long-term debt	[1]	0	0
Level 3 | Other long-term liabilities:
Liabilities:
Contingent consideration			0
Assumed contingent obligation		1,126	1,126
Contingent guaranteed obligation		0	75
Total other long-term liabilities:		1,126	1,201
Level 3 | Money markets | Cash and cash equivalents:
Assets:
Money markets		$ 0	$ 0
[1]	Fair value estimated using Level 2 inputs, which were quoted prices for identical or similar instruments in markets that are not active.

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3
Beginning balance	$ 1,579	$ 2,777	$ 5,869
Total net unrealized (gains) losses included in general and administrative expense in earnings	(265)	(687)	(2,585)
Net purchases, issuances, sales and settlements	(176)	(511)	(507)
Ending balance	1,138	1,579	2,777
Jet Prep Contingent Consideration | Jet Prep Ltd.
Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3
Beginning balance	0	751	2,722
Total net unrealized (gains) losses included in general and administrative expense in earnings	0	(751)	(1,971)
Net purchases, issuances, sales and settlements	0	0	0
Ending balance	0	0	751
Jet Prep Assumed Contingent Obligation | Jet Prep Ltd.
Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3
Beginning balance	1,138	1,138	1,752
Total net unrealized (gains) losses included in general and administrative expense in earnings	0	0	(614)
Net purchases, issuances, sales and settlements	0	0	0
Ending balance	1,138	1,138	1,138
Cantel Medical (U.K.) Contingent Guaranteed Obligation | Cantel Medical (UK) - PuriCore International Limited
Reconciliation of liability measured and recorded at fair value on a recurring basis using Level 3
Beginning balance	441	888	1,395
Total net unrealized (gains) losses included in general and administrative expense in earnings	(265)	64	0
Net purchases, issuances, sales and settlements	(176)	(511)	(507)
Ending balance	$ 0	$ 441	$ 888

Intangibles and Goodwill - Inta

Intangibles and Goodwill - Intangible Assets Summary (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 18,407	$ 13,095	$ 13,265
Gross	176,433	145,210
Accumulated Amortization	(59,469)	(41,002)
Net	116,964	104,208
Intangible assets with indefinite lives:
Trademarks and tradenames	7,548	7,511
Total intangible assets
Gross	183,981	152,721
Accumulated Amortization	(59,469)	(41,002)
Net	$ 124,512	111,719
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	20 years
Weighted average
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	12 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross	$ 119,576	100,649
Accumulated Amortization	(34,773)	(24,689)
Net	84,803	75,960
Total intangible assets
Accumulated Amortization	(34,773)	(24,689)
Technology
Finite-Lived Intangible Assets [Line Items]
Gross	42,794	32,767
Accumulated Amortization	(18,990)	(11,813)
Net	23,804	20,954
Total intangible assets
Accumulated Amortization	(18,990)	(11,813)
Brand names
Finite-Lived Intangible Assets [Line Items]
Gross	8,188	6,194
Accumulated Amortization	(3,225)	(2,394)
Net	4,963	3,800
Total intangible assets
Accumulated Amortization	(3,225)	(2,394)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross	3,092	3,092
Accumulated Amortization	(1,428)	(1,193)
Net	1,664	1,899
Total intangible assets
Accumulated Amortization	(1,428)	(1,193)
Patents and other registrations
Finite-Lived Intangible Assets [Line Items]
Gross	2,783	2,508
Accumulated Amortization	(1,053)	(913)
Net	1,730	1,595
Total intangible assets
Accumulated Amortization	$ (1,053)	$ (913)

Intangibles and Goodwill - Amor

Intangibles and Goodwill - Amortization Expense (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)
Estimated annual amortization expense of intangible assets for next five years
2,018	$ 15,617
2,019	15,293
2,020	13,539
2,021	13,204
2,022	12,821
Technology | Jet Prep Ltd.
Finite-Lived Intangible Assets [Line Items]
Accelerated depreciation due to disposal	$ 2,401

Intangibles and Goodwill - Good

Intangibles and Goodwill - Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Changes in Goodwill
Balance at the beginning of the period	$ 280,318	$ 241,951
Acquisitions	30,182	44,398
Foreign currency translation	945	(6,031)
Balance at the end of the period	311,445	280,318
Endoscopy
Changes in Goodwill
Balance at the beginning of the period	121,015	87,007
Acquisitions	8,193	40,047
Foreign currency translation	737	(6,039)
Balance at the end of the period	129,945	121,015
Water Purification and Filtration
Changes in Goodwill
Balance at the beginning of the period	58,880	58,872
Acquisitions	0	0
Foreign currency translation	208	8
Balance at the end of the period	59,088	58,880
Healthcare Disposables
Changes in Goodwill
Balance at the beginning of the period	92,290	87,939
Acquisitions	21,989	4,351
Foreign currency translation	0	0
Balance at the end of the period	114,279	92,290
Dialysis
Changes in Goodwill
Balance at the beginning of the period	8,133	8,133
Acquisitions	0	0
Foreign currency translation	0	0
Balance at the end of the period	$ 8,133	$ 8,133

Intangibles and Goodwill Intang

Intangibles and Goodwill Intangibles and Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended			17 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015	Jan. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of assets	$ 0	$ 0	$ 1,287
2013 License Agreement
Acquired Finite-Lived Intangible Assets [Line Items]
Payments made for license				$ 1,000

Warranties (Details)

Warranties (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Summary of activity in warranty reserves
Beginning balance	$ 2,575	$ 1,740
Acquisitions	179	28
Provisions	4,880	4,554
Settlements	(5,306)	(3,622)
Foreign currency translation	0	(125)
Ending balance	$ 2,328	$ 2,575

Financing Arrangements (Details

Financing Arrangements (Details) - USD ($)	Mar. 04, 2014	Sep. 28, 2017	Jul. 31, 2017	Jul. 31, 2016
Credit Agreement
Debt Instrument [Line Items]
Fees on unused portion of credit facilities (as a percent)			0.20%
Shares of foreign subsidiaries pledged as security (as a percent)			65.00%
Outstanding borrowings			$ 126,000,000
Credit Agreement | Minimum
Debt Instrument [Line Items]
Fees on unused portion of credit facilities (as a percent)			0.20%
Credit Agreement | Maximum
Debt Instrument [Line Items]
Fees on unused portion of credit facilities (as a percent)			0.40%
Credit Agreement | Lender's base rate
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			0.50%
Reference rate (as a percent)			4.00%
Credit Agreement | Lender's base rate | Minimum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			0.25%
Credit Agreement | Lender's base rate | Maximum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			1.25%
Credit Agreement | LIBOR
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			1.50%
Credit Agreement | LIBOR | Minimum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			1.25%
Reference rate (as a percent)			1.22%
Credit Agreement | LIBOR | Maximum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)			2.25%
Reference rate (as a percent)			1.31%
Credit Agreement | Other assets
Debt Instrument [Line Items]
Unamortized debt issuance costs			$ 580,000	$ 946,000
Revolving Credit Facility
Debt Instrument [Line Items]
Term of line of credit facility	5 years
Maximum borrowing capacity	$ 250,000,000
Maximum additional borrowing capacity available at the entity's option	100,000,000
Revolving Credit Facility | Subsequent Events
Debt Instrument [Line Items]
Amount borrowed		$ 61,300,000
Borrowings of foreign currency
Debt Instrument [Line Items]
Maximum borrowing capacity	100,000,000
Letters of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	30,000,000
Swing line loans
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 10,000,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Income Tax Disclosure [Abstract]
Consolidated effective tax rate (as a percent)	32.80%	36.20%	37.10%
Current
Federal	$ 28,900	$ 29,392	$ 24,602
State	4,352	4,433	3,920
International	1,545	1,863	1,165
Total	34,797	35,688	29,687
Deferred
Federal	2,020	(216)	(425)
State	261	(153)	(218)
International	(2,223)	(1,341)	(806)
Total	$ 58	$ (1,710)	$ (1,449)

Income Taxes - Geographic Compo

Income Taxes - Geographic Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Income Taxes
Income before income taxes	$ 106,233	$ 93,931	$ 76,191
United States
Income Taxes
Income before income taxes	108,329	92,744	73,645
International
Income Taxes
Income before income taxes	$ (2,096)	$ 1,187	$ 2,546

Income Taxes - Reconciliation (

Income Taxes - Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Expected statutory tax	35.00%	35.00%	35.00%
Differential attributable to:
Foreign operations	0.00%	0.60%	1.20%
State and local taxes	3.90%	3.20%	3.40%
Domestic production deduction	(2.70%)	(2.30%)	(2.40%)
Acquisition related items, net	0.10%	0.00%	(1.60%)
Loss on sale of business	0.00%	0.00%	1.10%
R&E tax credit	(1.40%)	(1.10%)	(0.50%)
Change in foreign tax rates	0.00%	(0.40%)	0.00%
Excess tax benefits	(2.20%)	0.00%	0.00%
Other	0.10%	1.20%	0.90%
Consolidated effective tax rate (as a percent)	32.80%	36.20%	37.10%
Share-based compensation, excess tax benefit, amount	$ 2,241	$ 1,179

Income Taxes - Deferred Taxes (

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Deferred tax assets:
Accrued expenses	$ 6,308	$ 5,140
Inventories	4,655	2,990
Accounts receivable	729	793
Other long-term liabilities	180	252
Stock-based compensation	3,402	3,665
Capital investment	545	546
Foreign NOLs	6,490	5,154
Subtotal	22,309	18,540
Valuation allowance	(2,984)	(2,334)
Deferred tax assets, net of valuation allowance	19,325	16,206
Deferred tax liabilities:
Property and equipment	(9,957)	(8,089)
Intangible assets	(20,107)	(19,818)
Goodwill	(13,975)	(11,878)
Deferred tax liabilities, gross	(44,039)	(39,785)
Net deferred tax liabilities - noncurrent	$ (24,714)	$ (23,579)

Income Taxes - Operating Loss C

Income Taxes - Operating Loss Carryforwards (Details) - Foreign $ in Thousands	Jul. 31, 2017USD ($)
Operating loss carryforwards
Net operating loss carryforwards (NOLs)	$ 6,490
Valuation allowance on NOLs	$ 2,984

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Repatriated dividends	$ 0	$ 0
Cumulative amount of undistributed earnings indefinitely reinvested in foreign subsidiaries	$ 44,509,000

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 7,715	$ 6,675	$ 6,025

Commitments and Contingencies72

Commitments and Contingencies - Annual Required Payments (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)
Minimum commitments under noncancelable operating leases
2,018	$ 6,522
2,019	5,278
2,020	3,779
2,021	2,719
2,022	1,231
Thereafter	2,454
Total	21,983
Jet Prep Ltd.
Total contractual obligations
Assumed contingent obligation	1,138
Decrease in contingent liability	$ 283

Accumulated Other Comprehensi73

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Components and changes in accumulated other comprehensive (loss) income
Other comprehensive income (loss)	$ 1,895	$ (13,019)	$ (8,328)
Accumulated Other Comprehensive Loss
Components and changes in accumulated other comprehensive (loss) income
Other comprehensive income (loss)	1,895	(13,019)	(8,328)
Foreign Currency Translation Adjustments
Components and changes in accumulated other comprehensive (loss) income
Balance	(11,795)	1,224	9,552
Other comprehensive loss before reclassification adjustments			(7,064)
Reclassification adjustment to loss on sale of business for foreign currency translation gain included in net income during the year			(1,264)
Other comprehensive income (loss)	1,895	(13,019)
Balance	$ (9,900)	$ (11,795)	$ 1,224

Earnings Per Common Share - Com

Earnings Per Common Share - Computation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Numerator for basic and diluted earnings per share:
Net income	$ 16,997	$ 17,511	$ 18,070	$ 18,800	$ 16,291	$ 14,019	$ 15,389	$ 14,254	$ 71,378	$ 59,953	$ 47,953
Less income allocated to participating securities									(431)	(488)	(433)
Net income available to common shareholders									$ 70,947	$ 59,465	$ 47,520
Denominator for basic and diluted earnings per share, as adjusted for participating securities:
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock (shares)									41,468,487	41,344,013	41,139,467
Dilutive effect of stock options using the treasury stock method and the average market price for the year (shares)									74,278	46,181	63,133
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock (shares)									41,542,765	41,390,194	41,202,600
Earnings per share attributable to common stock:
Basic earnings per share (in dollars per share)	$ 0.41	$ 0.42	$ 0.43	$ 0.45	$ 0.39	$ 0.34	$ 0.37	$ 0.34	$ 1.71	$ 1.44	$ 1.16
Diluted earnings per share (in dollars per share)	$ 0.41	$ 0.42	$ 0.43	$ 0.45	$ 0.39	$ 0.34	$ 0.37	$ 0.34	$ 1.71	$ 1.44	$ 1.15
Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been antidilutive									0	0	0

Earnings Per Common Share - Wei

Earnings Per Common Share - Weighted Average Shares (Details) - shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, to the entity's total weighted average number of shares and common stock equivalents, including participating securities
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock (shares)	41,542,765	41,390,194	41,202,600
Participating securities (in shares)	254,727	340,363	378,706
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities (shares)	41,797,492	41,730,557	41,581,306

Stock-Based Compensation - 2016

Stock-Based Compensation - 2016 Plan (Details)	12 Months Ended
	Jul. 31, 2017Installmentshares	Jul. 31, 2016shares	Jan. 31, 2016shares	Jul. 31, 2015shares	Jul. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding unvested restricted stock shares	222,298,000	331,367,000		343,519,000	525,842,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options (in shares)	122,500	122,500		107,500
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares authorized for issuance			1,200,000
Number of anniversaries of grant date on which awards vest | Installment	3
Outstanding unvested restricted stock shares	113,926
Outstanding options (in shares)		0
Shares available under Plan	1,086,911
2016 Plan | First anniversary vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	1 year
2016 Plan | Second anniversary vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	2 years
2016 Plan | Third anniversary vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	3 years

Stock-Based Compensation - 2006

Stock-Based Compensation - 2006 Plan (Details)	12 Months Ended
	Jul. 31, 2017Installmentshares	Jul. 31, 2016shares	Jul. 31, 2015shares	Jul. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding unvested restricted stock shares	222,298,000	331,367,000	343,519,000	525,842,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options (in shares)	122,500	122,500	107,500
2006 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares authorized for issuance	5,591,000
2006 Plan | Stock options and stock appreciation rights
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares authorized for issuance	2,700,000
2006 Plan | Restricted stock and other stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares authorized for issuance	2,891,000
2006 Plan | Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of anniversaries of grant date on which awards vest | Installment	3
Outstanding unvested restricted stock shares	108,372
2006 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options (in shares)	122,500
First anniversary vesting | 2006 Plan | Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	1 year
First anniversary vesting | 2006 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	1 year
Second anniversary vesting | 2006 Plan | Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	2 years
Second anniversary vesting | 2006 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	2 years
Third anniversary vesting | 2006 Plan | Restricted shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	3 years
Third anniversary vesting | 2006 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	33.33%
Vesting period	3 years

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	$ 8,844	$ 8,361	$ 5,867
Total unrecognized stock-based compensation cost (in dollars)	$ 9,741
Remaining weighted average period for unrecognized compensation cost	17 months
Cost of sales
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	$ 371	438	270
Selling
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	1,582	929	608
General and administrative
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	6,774	6,881	4,897
Research and development
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	117	113	92
Total operating expenses
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation before income taxes	$ 8,473	$ 7,923	$ 5,597

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value Monte Carlo Simulation (Details) - Restricted shares	12 Months Ended
	Jul. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility of common stock	27.75%
Average volatility of peer companies	32.98%
Average correlation coefficient of peer companies	35.35%
Risk-free interest rate	0.96%

Stock-Based Compensation - Nonv

Stock-Based Compensation - Nonvested Stock Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)		331,367,000	343,519,000	525,842,000
Granted (in shares)		113,065,000	175,700,000	144,278,000
Vested (in shares)	[1]	(216,212,000)	(183,045,000)	(313,797,000)
Forfeited (in shares)		(5,922,000)	(4,807,000)	(12,804,000)
Nonvested stock awards at the end of the period (in shares)		222,298,000	331,367,000	343,519,000
Weighted Average Fair Value
Nonvested stock awards at the beginning of the period (in dollars per share)		$ 46.09	$ 32.77	$ 22.25
Granted (in dollars per share)		81.77	55.40	39.77
Vested (in dollars per share)	[1]	43.62	30.06	18.62
Forfeited (in dollars per share)		59.40	45.06	26.20
Nonvested stock awards at the end of the period (in dollars per share)		$ 66.28	$ 46.09	$ 32.77
Aggregate fair value, vested in period		$ 9,431	$ 5,503	$ 5,844
Number of Time-based Shares
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)		331,367,000	343,519,000	525,842,000
Granted (in shares)		86,305,000	175,700,000	144,278,000
Vested (in shares)	[1]	(214,932,000)	(183,045,000)	(313,797,000)
Forfeited (in shares)		(5,922,000)	(4,807,000)	(12,804,000)
Nonvested stock awards at the end of the period (in shares)		196,818,000	331,367,000	343,519,000
Number of Performance-based Shares
Number of Shares
Granted (in shares)		16,960,000
Vested (in shares)	[1]	(725,000)
Nonvested stock awards at the end of the period (in shares)		16,235,000
Number of Market-based Shares
Number of Shares
Granted (in shares)		9,800,000
Vested (in shares)	[1]	(555,000)
Nonvested stock awards at the end of the period (in shares)		9,245,000
[1]	The aggregate fair value of all nonvested stock awards which vested was approximately $9,431, $5,503 and $5,844 in fiscal 2017, 2016 and 2015, respectively.

Stock-Based Compensation - FV A

Stock-Based Compensation - FV Assumptions (Details) - Stock options		12 Months Ended
		Jul. 31, 2016	Jul. 31, 2015
Weighted-Average Black-Scholes Option Valuation Assumptions
Dividend yield		0.22%	0.25%
Volatility of common stock	[1]	55.90%	33.90%
Risk-free interest rate	[2]	1.41%	1.55%
Expected lives (in years)	[3]	5 years	5 years
[1]	Volatility was based on historical closing prices of our common stock.
[2]	The U.S. Treasury rate based on the expected life at the date of grant.
[3]	Based on historical exercise behavior.

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Options Outstanding
Number Outstanding (in shares)	122,500	122,500
Weighted Average Exercise Price (in dollars per share)	$ 29.36	$ 29.36
Weighted Average Remaining Contractual Life	15 months 7 days
Aggregate Intrinsic Value	$ 5,493
Options Exercisable
Number Exercisable (in shares)	104,167
Weighted Average Exercise Price (in dollars per share)	$ 26.28
Weighted Average Remaining Contractual Life	12 months 7 days
Aggregate Intrinsic Value	$ 4,992
Stock-based awards, additional disclosure
Deduction in income tax due to exercise of options and vesting of restricted stock (in dollars)	5,592	$ 3,059
Reduction in income tax expense over the equity awards' vesting period	3,351	1,880
Share-based compensation, excess tax benefit, amount	2,241	1,179
Stock options
Options Outstanding
Aggregate Intrinsic Value	$ 5,493	$ 4,605	$ 3,133
Stock options, additional disclosure
Options vested during period (in shares)	23,333	35,834	27,500
Aggregate fair value of all options vested (in dollars)	$ 349	$ 344	$ 248
Weighted average fair value of all options granted (in dollars per share)		$ 26.49	$ 11.54
Outstanding options (in shares)	122,500	122,500	107,500
Exercise of stock options (in shares)	89,607	67,038
Total average price per share	$ 77.12	$ 55.68

Retirement Plans (Details)

Retirement Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Retirement Benefits [Abstract]
Aggregate employer contributions recognized under 401(k) Savings and Retirement Plans	$ 3,863	$ 3,406	$ 2,541

Information as to Reportable 84

Information as to Reportable Segments and Foreign and Domestic Operations - Concentration Risk (Details) - Customer concentration - Segment sales	12 Months Ended
	Jul. 31, 2017
Water Purification and Filtration
Concentration risk
Concentration risk within segment (as a percent)	50.20%
Healthcare Disposables
Concentration risk
Concentration risk within segment (as a percent)	43.40%
Dialysis
Concentration risk
Concentration risk within segment (as a percent)	44.20%

Information as to Reportable 85

Information as to Reportable Segments and Foreign and Domestic Operations Information as to Reportable Segments and Foreign and Domestic Operations - Other (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Segment Reporting Information [Line Items]
Loss on sale of business	$ 0	$ 0	$ 2,206
Disposal by sale | Specialty Packaging business | Other
Segment Reporting Information [Line Items]
Loss on sale of business			$ 2,206

Information as to Reportable 86

Information as to Reportable Segments and Foreign and Domestic Operations - Operating Segment (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Segment Reporting Information [Line Items]
Net sales	$ 205,502	$ 192,113	$ 184,817	$ 187,725	$ 179,002	$ 173,703	$ 158,271	$ 153,779	$ 770,157	$ 664,755	$ 565,004
Operating income:									110,410	97,251	80,761
Interest expense, net									4,303	3,320	2,364
Other income									(126)	0	0
Loss on sale of business									0	0	2,206
Income before income taxes									106,233	93,931	76,191
Identifiable assets:	786,373				694,532				786,373	694,532	584,031
Capital expenditures:									27,065	18,889	12,760
Depreciation and amortization:									33,452	25,084	23,957
Operating Segment
Segment Reporting Information [Line Items]
Operating income:									142,753	124,034	99,240
General corporate
Segment Reporting Information [Line Items]
Operating income:									32,343	26,783	18,479
Identifiable assets:	44,537				31,629				44,537	31,629	35,320
Capital expenditures:									5,772	941	234
Depreciation and amortization:									518	268	157
Endoscopy
Segment Reporting Information [Line Items]
Net sales									398,773	341,752	248,654
Endoscopy | Operating Segment
Segment Reporting Information [Line Items]
Operating income:									73,440	61,021	40,863
Identifiable assets:	368,820				347,107				368,820	347,107	238,799
Capital expenditures:									13,816	11,299	7,042
Depreciation and amortization:									18,245	14,333	10,729
Water Purification and Filtration
Segment Reporting Information [Line Items]
Net sales									196,446	177,669	173,834
Water Purification and Filtration | Operating Segment
Segment Reporting Information [Line Items]
Operating income:									33,159	30,620	30,606
Identifiable assets:	147,477				137,731				147,477	137,731	138,069
Capital expenditures:									3,689	3,376	2,984
Depreciation and amortization:									5,706	5,441	5,257
Healthcare Disposables
Segment Reporting Information [Line Items]
Net sales									144,457	112,584	106,920
Healthcare Disposables | Operating Segment
Segment Reporting Information [Line Items]
Operating income:									28,000	24,486	19,904
Identifiable assets:	208,328				157,918				208,328	157,918	145,391
Capital expenditures:									2,492	2,606	1,587
Depreciation and amortization:									8,556	4,361	6,354
Dialysis
Segment Reporting Information [Line Items]
Net sales									30,481	32,750	31,240
Dialysis | Operating Segment
Segment Reporting Information [Line Items]
Operating income:									8,154	7,907	6,749
Identifiable assets:	$ 17,211				$ 20,147				17,211	20,147	26,452
Capital expenditures:									1,296	667	894
Depreciation and amortization:									427	681	1,382
Other
Segment Reporting Information [Line Items]
Net sales									0	0	4,356
Other | Operating Segment
Segment Reporting Information [Line Items]
Operating income:									0	0	1,118
Capital expenditures:									0	0	19
Depreciation and amortization:									$ 0	$ 0	$ 78

Information as to Reportable 87

Information as to Reportable Segments and Foreign and Domestic Operations - Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Net sales
Net sales	$ 205,502	$ 192,113	$ 184,817	$ 187,725	$ 179,002	$ 173,703	$ 158,271	$ 153,779	$ 770,157	$ 664,755	$ 565,004
Total long-lived assets:	93,045				79,753				93,045	79,753	67,883
Goodwill and intangible assets, net	435,957				392,037				435,957	392,037	327,787
Total	529,002				471,790				529,002	471,790	395,670
United States
Net sales
Net sales									599,657	515,055	447,848
Total long-lived assets:	74,401				62,820				74,401	62,820	57,080
Europe/Africa/Middle East
Net sales
Net sales									95,753	88,355	62,193
Total long-lived assets:	16,209				14,863				16,209	14,863	9,122
Asia/Pacific
Net sales
Net sales									40,964	33,374	28,529
Total long-lived assets:	1,381				1,607				1,381	1,607	1,081
Canada
Net sales
Net sales									26,648	20,975	19,306
Total long-lived assets:	$ 1,054				$ 463				1,054	463	600
Latin America/South America
Net sales
Net sales									$ 7,135	$ 6,996	$ 7,128

Quarterly Results of Operatio88

Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 205,502	$ 192,113	$ 184,817	$ 187,725	$ 179,002	$ 173,703	$ 158,271	$ 153,779	$ 770,157	$ 664,755	$ 565,004
Cost of sales	107,774	100,665	96,340	98,218	93,672	93,382	85,934	82,581	402,997	355,569	311,537
Gross profit	$ 97,728	$ 91,448	$ 88,477	$ 89,507	$ 85,330	$ 80,321	$ 72,337	$ 71,198	367,160	309,186	253,467
Gross profit percentage	47.60%	47.60%	47.90%	47.70%	47.70%	46.20%	45.70%	46.30%
Net income	$ 16,997	$ 17,511	$ 18,070	$ 18,800	$ 16,291	$ 14,019	$ 15,389	$ 14,254	$ 71,378	$ 59,953	$ 47,953
Earnings per common share:
Basic (in dollars per share)	$ 0.41	$ 0.42	$ 0.43	$ 0.45	$ 0.39	$ 0.34	$ 0.37	$ 0.34	$ 1.71	$ 1.44	$ 1.16
Diluted (in dollars per share)	$ 0.41	$ 0.42	$ 0.43	$ 0.45	$ 0.39	$ 0.34	$ 0.37	$ 0.34	$ 1.71	$ 1.44	$ 1.15

SCHEDULE II - VALUATION AND Q89

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016		Jul. 31, 2015
Allowance for doubtful accounts:
Changes in allowance for doubtful accounts
Balance at Beginning of Period	$ 1,850	$ 2,092		$ 1,874
Additions	998	15		464
Deductions	(1,056)	(223)		(227)
Translation Adjustments	16	(34)		(19)
Balance at End of Period	1,808	1,850		2,092
Reserve for excess and obsolete inventory:
Changes in allowance for doubtful accounts
Balance at Beginning of Period	5,390	3,895		4,419
Additions	5,016	3,182		1,494
Deductions	(1,580)	(1,569)		(1,796)
Translation Adjustments	27	(118)		(222)
Balance at End of Period	8,853	5,390		3,895
Deferred tax asset valuation allowance:
Changes in allowance for doubtful accounts
Balance at Beginning of Period	2,334	2,037		3,538
Additions	615	929		1,010	[1]
Deductions	0	(712)	[1]	(2,420)
Translation Adjustments	35	80		(91)
Balance at End of Period	$ 2,984	$ 2,334		$ 2,037
[1]	The amounts primarily include deductions of valuation allowances associated with New Jersey net operating losses.